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ABSTRACT OF THE DISSERTATION 
THE EFFECT OF TARGET-SPECIFIC BIOMOLECULES IN BREAST CANCER 
by 
Mohannad Mrwan Garoub 
Florida International University, 2017 
Miami, Florida 
Professor Marcus S. Cooke, Co-Major Professor 
Professor Stanislaw Wnuk, Co-Major Professor 
Cancer is the second leading cause of mortality in the United States and the World, 
therefore, early effective prevention, diagnosis, and therapy is needed. Estrogens play a 
major role in the initiation and progression of breast cancer. Elevated lifetime exposure to 
estrogens is associated with an increased risk of developing breast cancer. Estrogens 
through influencing mitochondria contribute to estrogen induced breast carcinogenesis; 
however, the exact mitochondrial mechanisms underlying the estrogen carcinogenic effect 
in breast tissue are not clearly understood. For this dissertation, the mitotoxic and cytotoxic 
effects of triphenylphosphonium cation (TPP) and Origanum majorana organic extract 
(OME) as well as PEGylated bioconjugate of OME with TPP (P-OME-TPP) against human 
breast epithelial and cancer cell lines was investigated. Initially, TPP, a lipophilic cation, 
was used to check whether an imbalance in mitochondrial bioenergetics, in part, may be 
responsible for estrogen induced growth of breast cancer. The results showed that exposure 
of estrogen-dependent MCF-7 cells to 17 β-estradiol (E2) induced the metabolic activity, 
proliferation, mitochondrial bioenergetics, DNA damage, and formation of cellular and 
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mitochondrial reactive oxidant species (ROS). These E2-induced endpoints were inhibited 
by co-treatment with TPP, indicating mitochondrial mechanisms, in part, may contribute 
to the development of breast cancer. Furthermore, O. majorana, widely used in the Middle 
East as a culinary aromatic medicinal herb, has been shown to possess an extensive range 
of biological activity including antioxidant, anti-inflammatory, and anti-tumor growth 
effects. Interestingly, the anticancer potential of O. majorana against breast cancer remains 
largely unexplored; therefore, the anticancer effect of O. majorana on breast cell lines was 
investigated. The results showed that E2-induced metabolic activity and growth were 
inhibited by OME in MCF-7 cells. The results also demonstrated that synthesized P-OME-
TPP conjugate, compared to OME, was far more effective in exerting its cytotoxic effect 
through the inhibition of growth and mitochondrial metabolic activity in both highly 
metastatic, triple negative MDA-MB-231 and estrogen-dependent MCF-7 breast cancer 
cells. Altogether, these findings offer a new perspective on the utility of mitochondria-
targeted lipophilic TPP cation and the potential of O. majorana extract to be developed as 
a new therapy against breast tumors. 
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CHAPTER 1  
1.1 INTRODUCTION 
Breast cancer is the most common cancer in women and the second most common cancer 
among all cancers worldwide, and in the United States.1 In 2017, almost 30% (255,180 out 
of 852,630 cases) of newly diagnosed cases and 14% (41,070 out of 282,500 cases) of 
cancer-related deaths are expected breast cancer cases among all cancer sites in female, in 
the USA.1 These high rates are probably due to the interaction of several environmental 
and biological factors. These interactions, genetically and epigenetically, make breast 
cancer a heterogeneous disease, which leads to therapeutic challenges including resistance 
and recurrence, and the need for extremely toxic therapeutic options. Indeed, almost half 
of breast cancer patients are treated with hormonal therapy and chemotherapy; however, 
35% of those patients are resistant to this therapy.2 Treatments against aggressive tumors, 
usually resistant to therapy, are not effective. The existing therapeutic agents used on 
aggressive tumors, such as chemotherapy, are extremely toxic.3 There is an urgent need to 
develop more effective and less toxic therapy against aggressive breast cancer. To achieve 
this, it is necessary to develop therapies based on the clinical and molecular characteristics 
of the tumor. Based on gene expression profiles, there are at least three significant 
subtypes.4 Estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) receptor status are very important in categorizing breast 
tumors to successfully predict outcome and help in treating the disease.5 
For years, estrogen was suspected to play major role in cancer, since strong 
epidemiological and clinical evidence linked exposure to estrogens with increased risk of 
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developing breast, endometrial, and uterine cancers.6–8 Elevated lifetime exposure of 
estrogen is caused by early menstruating and/or late-onset menopause; however, the exact 
routes of estrogens take in promoting tumor development are not clearly understood. The 
National Institute of Environmental Health Sciences added estrogen to its list of known 
cancer-causing agents, due to its capability to induce and promote the development of 
malignant neoplasms.9–12 In addition, breast cancer characterized by lack of ER, PR, and 
HER2, often called triple-negative breast cancer (TNBC), is typically associated with poor 
prognosis due to aggressive tumor phenotypes and current lack of effective and specific 
therapies.13 Traditional chemotherapy drugs cause non-specific and toxic off-target effects 
on normal tissues, deteriorate the patient's quality of life, and weaken the immune system.14  
Mitochondria are considered important bioenergetic and biosynthetic factories that 
play a critical role in cellular metabolism, calcium homeostasis, redox signaling, apoptosis 
and cell death.15 Tumor cells are characterized by dysfunctional mitochondria, which is 
demonstrated by the mitochondrial respiration defects that shift the source of metabolic 
energy from oxidative phosphorylation to active glycolysis and increase reactive oxygen 
species (ROS) production.16 Estrogens have been shown to increase mitochondria-derived 
ROS (mt ROS) that might contribute to breast carcinogenesis, although the exact role of 
mitochondria in the carcinogenic effect is unclear.17 One of the few proposed mechanisms 
suggested that E2-induced mt ROS can act as signal transducing messengers by activating 
the binding of oxidant-sensitive transcription factors known to be involved in the regulation 
of cell cycle genes.18 Moreover, specific mitochondrial activities can contribute to the 
initiation and progression of tumor growth.19 For instance, mechanisms involved in cancer 
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cell metabolic reprogramming have been shown to be associated with oncogenic signals.20 
In recent years, mitochondria have been recognized as a potential therapeutic target in 
cancer therapy, a concept that has emerged and is an acknowledged area of reaseach.21 
Mitochondria-specific accumulation of therapeutic agents is necessary in 
optimizing the therapeutic efficacy of tumor-targeted drugs. A broad applicable approach 
in mitochondria-specific delivery is using triphenylphosphonium (TPP) cation to deliver 
various bioactive molecules to mitochondria including antioxidants.22 TPP is a lipophilic 
cation, which allows it to pass through the phospholipid bilayers of the cell membrane and 
mitochondria.23 The large mitochondrial membrane potential, approximately -180 mV, 
across the membrane layers allows the uptake and accumulation of TPP in mitochondria.23 
An increasing number of studies have shown evidence that phytochemicals are 
important with regards to their cancer chemoprevention properties and their ability to 
decrease tumor growth.24 Phytochemicals can regulate several pathways used by cancer 
cells in the processes of cell growth and proliferation, survival, angiogenesis, invasion, 
metastasis, and apoptosis.25 Origanum majorana, commonly known as marjoram, is 
worldwide perennial herb. It is utilized as a spice, flavoring agent, and has an ancient 
culinary and medicinal use. It has been used as traditional medicine for various illnesses 
such as chest infections, cough, sore throat, rheumatism, cardiovascular diseases, stomach 
ache, as well as skin care. Several studies have reported that O. majorana is rich in phenolic 
compounds, which possess the capacity to scavenge free radicals and exhibit strong 
antioxidant properties.26 A few studies have reported the anticancer potential of O. 
majorana; however, it remains largely unexplored.27  
4 
 
To increase drugs efficacy and lower their toxicity, small molecule bioconjugation 
therapy could be the solution, since it has the ability to specifically target and safely reach 
tumor core, due to its unique physical and biological properties.28 Polyethylene glycol 
(PEG), is an amphiphilic polymer, which provides electrostatic and steric stabilization, and 
a longer circulation half-life in vivo as well as functional-end groups for the attachment of 
targeting ligands such as antibodies, peptides and aptamers.28 PEGylation of anticancer 
molecules is to protect the molecules from destruction by the reticuloendothelial system 
(RES) and, therefore, increase circulation time and drug accumulation in the tumors.29 
Thus, developing target specific PEG conjugate with O. majorana and TPP as therapeutic 
molecules against breast cancer cells is a rational approach for breast cancer therapy. The 
novel concept of this study was a bioconjugation approach that involves PEGylation of 
natural anti-tumor compounds and specific mitochondria targeting molecules for 
specifically preventing growth of breast cancer and possibly other types of cancers. 
1.2 HYPOTHESIS AND SPECIFIC AIMS 
It is hypothesized that novel mitochondria-targeted bioconjugates of O. majorana organic 
extract (OME) with polyethylene glycol (PEG) and triphenylphosphonium (TPP), inhibits 
the growth of breast cancer cells. 
In order to test this hypothesis, the following specific aims have been identified:  
Aim 1. To test the effect of the mitochondria-targeted lipophilic cation TPP, E2, and co-
treatment of E2 with TPP in estrogen-dependent breast cancer (MCF-7), metastatic breast 
cancer (MDA-MB231), and normal epithelial breast (MCF-10A) cells. The purpose of this 
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aim is to elucidate the functions by which mitochondria contribute to the growth of breast 
cancer. Cell viability, cell growth, and cell proliferation assays were used to study the 
cytotoxic effect of TPP and its E2 co-treatment. Mitochondrial bioenergetics, cellular and 
mitochondrial ROS production, and DNA damage assays were used to identify potential 
molecular effect of TPP, E2, and co-treatment of E2 with TPP. 
Aim 2. To synthesize and test a small molecule bioconjugate of OME with PEG and TPP 
(P-OME-TPP). The purpose of this aim is to test the potential cytotoxic effects of OME as 
well as P-OME-TPP against MCF-7, MDA-MB213, and MCF-10A cell lines in the 
presence and absence of E2. Cell viability and cell growth assays were used to study the 
cytotoxic effectiveness of OME and P-OME-TPP. The findings of this study will determine 
the possible antitumor properties of OME and P-OME-TPP as a potential breast cancer 
therapy.  
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CHAPTER 2 
LITERATURE REVIEW 
CURRENT STATUS OF TARGETING BREAST CANCER STEM CELLS USING 
SMALL MOLECULE-BASED THERAPY FOR TRIPLE NEGATIVE 
AGGRESSIVE BREAST CANCER 
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2.1 Abstract 
Breast cancer is the most common malignancies among women and about 20% of this 
disease is represented by triple negative breast carcinoma (TNBC). Triple-negative breast 
cancer, characterized by tumors lacking expression of estrogen receptor, progesterone 
receptor, or human epidermal growth factor 2 amplification, impose a clinical challenge 
because they are often resistant to conventional therapy. Due to the absence of well-defined 
molecular targets, the aggressive nature of TNBC, poor prognosis, and low efficacy and 
high toxicity of existing therapeutic agents, identification of prognostic factors and markers 
to identify a novel treatment approach is utmost needed therapy for this disease. Cancer 
stem cells (CSCs) are predicted to mediate tumor recurrence after therapy due to their 
properties of self-renewal and differentiation. Tumor resistance to therapy is linked to both 
CSCs and dysfunctional mitochondria. Recently, targeted therapeutic approaches have 
been utilized in breast cancer and other types of cancer. Developing target-specific therapy 
for CSCs signaling pathways and mitochondrial functions could be a possible approach for 
TNBC. In this sense, nanoparticle-based therapy is capable of combining various targeted 
molecules that specifically and safely reach the tumor with enhanced efficacy and low 
toxicity. This review focuses on the characterization and function of CSCs and their role 
in breast cancer, potential roles of several molecular markers in aggressive breast cancer 
stem cells (BCSCs), and mitochondrial role in cancer and CSCs as a potential target for 
therapy, as well as various potential nano-therapy approaches for breast cancer.  
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2.2 Introduction 
Breast cancer is the most frequently diagnosed cancer in women and the second most 
common cancer among all cancers worldwide and in the United States.1 In 2017, more than 
255,000 new cases of breast cancer are expected in the USA, with almost 42,000 cancer-
related deaths (Table 2.2.1).1 The probable cause of these high rates could be the interaction 
of multiple environmental and biological factors. These interactions contribute to the 
heterogeneity of the disease, which lead to therapeutic challenges such as disease resistance 
and recurrence, and the need of highly toxic therapy.2 Treatments against aggressive breast 
tumor are usually not effective due to disease resistance to existing therapy such as 
chemotherapy, which is usually immensely toxic.3 There is a necessity of developing an 
effective and less toxic therapy against aggressive breast cancer. It is necessary to establish 
therapies according to the molecular characteristics of the tumor to achieve a better 
treatment with increased efficacy and low toxicity. 
Breast cancer; biologically and molecularly, is classified into different subtypes, 
which play a significant role in the prognosis and treatment of the diseases.4 There are at 
least three significant subtypes have been identified based on gene expression profiles, 
which include estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor 2 (HER-2) receptor.5 The status of these gene expression profiles is essential 
in subcategorizing breast tumors for better outcome prediction and help in controlling 
disease progression and developing targeted treatment.6 
Estrogens are considered a major risk factor for breast cancer initiation and 
progression. Epidemiological and clinical evidence have linked elevated lifetime exposure  
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 Estimated New Cases Estimated Deaths 
Breast Cancer 
Male Female Both sexes Male Female Both sexes 
2,470 252,710 255,180 460 40,610 41,070 
Percentage* 30% 14% 
*Percentages of all sites (100%) in female; new cases (852,630); deaths (282,500). 
Table 2.2.1 Estimated Number and Percentage of New Breast Cancer Cases and Deaths. The 
estimated incidence and mortality data are sorted by sex and reported by American Cancer Society. 
Data are representative in the US populations for year 2017.1 
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to estrogen with high risk of developing breast cancer.7–9 However, the exact mechanisms 
of estrogens carcinogenic effect involvement in breast tissue are still not widely explored. 
Since they possess the ability of initiating and promoting the development of breast 
malignancy, estrogens are considered, experimentally, breast carcinogens.10–13 ER 
signaling pathways are one of the most identified pathways in estrogen carcinogenic 
mechanisms.14,15 As most types of hormonal therapies for breast cancer are for ER+ and/or 
PR+ cancers, they are generally limited to anti-estrogenic and/or anti-progesteronic agents 
targeting their receptors.16 Although, 70% of newly diagnosed breast cancers patients are 
ER+, up to 50% of those patients develop resistance to most of the hormonal therapeutic 
agents.17 Furthermore, breast cancers with overexpression of HER-2 (HER-2-positive), 
which is overexpressed on the cancer cell surface of almost 20% of breast cancer patients,6 
tend to grow and spread more aggressively than HER-2-negative.18 HER-2 gene 
amplification, which is associated with HER-2 protein overexpression in breast cancer, has 
been linked with promotion of tumorigenesis such as increased cell proliferation, tumor 
invasiveness, aggressive metastases, higher angiogenesis, and declined apoptosis.19 
Several drugs have been developed to target ER and the receptor of HER-2 protein to 
inhibit pathways that overexpress the epidermal growth factor (EGF) receptors in the cell 
membrane.20 However, patients which lack ER and overexpress HER-2 are unresponsive 
to these types of therapies.21 
The last course of action when hormone therapy (ER+) and protein targeted therapy 
(HER-2-positive) prove unresponsive is usually chemotherapy. Chemotherapy is mainly 
used for patients with advanced breast cancer, where the cancer has developed resistance 
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to conventional therapy and distant metastasis. For early breast cancer stages, some 
common chemotherapy drugs used in treatment include anthracyclines; such as 
Doxorubicin and Epirubicin, and taxanes; such as Paclitaxel and Docetaxel.22 For advanced 
breast cancer stages, a combination of drugs are used including Docetaxel, Paclitaxel, 
Platinum agents, Vinorelbine, Capecitabine, Liposomal doxorubicin, Gemcitabine and 
more.22 The potency of these chemotherapy drugs on in vitro cancer cells is clearly 
demonstrated at even nanomolar levels.23 However, due to their non-specific effects in the 
body on normal tissues, these drugs cause toxicity, deteriorate the patient's quality of life, 
weaken the host immune system, and result in a severe damage to human's own recovery 
power.23 Their effective mechanisms are usually on cells that actively growing and dividing 
quickly, which is why they work against rapidly dividing and growing cancer cells. 
However, many normal cells in the body, such those in the bone marrow, mucosal cells in 
the mouth, lining of the intestines, and hair follicles, also divide rapidly, which are the most 
likely off-target cells to be affected by these drugs and can lead to very toxic side effects 
including death.22 Radiation therapy and/or surgery could be involved in the treatment of 
breast cancer and also could be combined with chemotherapy for certain advanced/late 
stages of breast cancer.24 
Breast cancer characterized by lack of ER+, PR+, and HER-2-positive, often called 
TNBC, is usually associated with poor prognosis due to aggressive tumor phenotypes and 
current lack of effective and specific therapies and poor response to toxic chemotherapy.25 
TNBC contains stem cells of different origins and each one of which may not be killed by 
only one specific therapeutic agent. CSCs possess several characteristics including self-
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renewal, pluripotency and tumorigenicity and form a rare population in a tumor tissue (11-
30 percent in breast tumor).26 Because this small population of CSCs is thought to be more 
resistance to chemotherapy than the major tumor cells and conventional cancer therapies 
do not eradicate these cells, and responsible for tumor relapse and metastasis.26 Therefore, 
CSCs need to be specifically targeted and destroyed to reach total tumor elimination, a 
concept that has started to change approaches to cancer therapy treatment (Figure 2.2.1).27 
Specific mitochondria activities have been linked to the initiation and progression 
of tumor growth.28 Dysfunctional mitochondria is common among several cancer cells and 
mechanisms involved in cancer cell metabolic changes have been associated with 
oncogenic signals.27 This has attracted attention of multiple research and clinical 
investigations on mitochondria-targeting as a cancer therapeutic approach. Mitochondrial 
targeting could be achieved through a specific carrier that mediates multiple delivery 
molecules including mitochondrial apoptotic agents or chemicals. Nanotechnology-based 
therapy has the ability to specifically target and reach the tumor with increased efficacy 
and low toxicity due to their unique physical and biological properties.23 At present, 
nanomedicine is considered a new medical science with rapid growth and development, 
and its nanotherapy approaches can be diagnostic or therapeutic.23 Nanocarriers like 
liposomes and micelles offer a non-chemical approach to modify the disposition of drug 
molecules.28 For instance, liposomes and nanoparticles can be modified with antibodies or 
other targeting ligands to achieve cell-specific recognition.29 Nanocarriers could be the 
ultimate tool in mitochondria-targeted anticancer approaches, since they not only achieve 
tumor-specific accumulation of a drug but also mediate mitochondria-specific 
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Figure 2.2.1 Therapy Targeting Cancer Stem Cells is Effective in Total Tumor Elimination. 
Cancer cells targeted therapy might be able to reduce the tumor size and development, but due to 
CSCs self-renewal property, tumor usually grow back and metastasize. In CSCs targeted therapy, 
the tumor usually reduces and deteriorates due to the absence of self-renewal property.  
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accumulation within a tumor cell.29 In recent years, targeted therapy approaches took over 
conventional therapies in breast cancer and in many other cancers. As a therapy for TNBC 
is very challenging and difficult due to the absence of specific targets and markers, 
developing target-specific nano-therapeutic molecules against mitochondria and its 
regulated genes and proteins in TNBC and TNBC stem cells is a promising approach for 
TNBC therapy. In this review, CSCs and BCSCs, some molecular markers for TNBC, 
mitochondrial targeting in cancer and cancer stem cells, nanoparticles applications and 
approaches in breast cancer and BCSCs are discussed in details. 
2.3 Cancer Stem Cells & Breast Cancer Stem Cells 
Cancer development involves several steps and processes where healthy and normal cells 
undergo several stages of mutation that change them to abnormal cells that grow 
uncontrollably. Part of the multistep process to cancer includes acquiring damage and 
mutations to genes that normally regulate cell proliferation (Figure 2.3.1).30 Accumulation 
of damage in these genes can result in uncontrolled cell proliferation, which can lead cells 
to break away from the primary tumor and form cancers at other sites in the body, a process 
called metastasis.31 There is a growing body of evidence that supports the concept that 
CSCs are capable of both tumor initiation and sustaining tumor growth.32 It is believed as 
a result from the sequential and progressive accumulation of genetic instability, adult stem 
cells appear to be an appropriate initial target for malignant transformation due to their long 
lifespans during tumor development.32 CSCs share several properties with normal stem 
cells, such as capacity for self-renewal and ability to differentiate.32 Recently, there have 
been extended efforts focused on identifying molecules that control the generation and cells 
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Figure 2.3.1 Emergence of Cancer Cells. Normal cell division result in many copies of cells and 
some copies may have accumulated DNA damage. Repair mechanisms of the cell may repair the 
damage or the cell may undergo apoptosis. In cancer, mutations are carried on for several cell 
divisions, which eventually result in uncontrollable growth and cancer. Normal cells may have 
some nuclear mutations which will lead to inflammation, precancer and finally cancer due to the 
uncontrolled cell division or growth.33 
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survival of CSCs. For identifying CSCs from tumor cells, markers specific for normal stem 
cells of the same organ are commonly used. Indeed, number of cell surface markers has 
been effectively used in the identification of CSCs including CD133, CD44, CD24, 
EpCAM, THY1, ATP-binding cassette B5, and CD200.34 Specifically, BCSCs have been 
identified by the enrichment of two subpopulations including CD44+/CD24-/low and 
ALDH+.34 
CD44 is an adhesion molecule with multiple isoforms that has pleiotropic roles in 
signaling, migration and homeostasis.35 In 2003, Al-Hajj et al. made the initial discovery 
of BCSCs when they revealed a cellular population from human breast cancer tumors 
characterized by the cell-surface markers CD44+/CD24-/low.34 They found that the 
CD44+/CD24-/low subpopulation in tumors was highly tumorigenic. They obtained 
CD44+/CD24-/low cells from a primary site or metastatic pleural effusions, around 1000 
cells, gave rise to tumors when xenotransplanted into NOD/SCID mice.34 In addition, 
CD44 is a fusogenic factor that implies that CSCs may have the capacity to fuse with other 
cell types, which explains the detection of fusogenic proteins commonly associated with 
neoplastic malignances.36  
ALDH activity has been identified, and widely used, as a CSC marker for a variety 
of malignancies, including lung, liver, bone, colon, pancreatic, prostate, head and neck, 
bladder, thyroid, brain, melanoma and cervical cancers.37–47 Ginestier et al. reported that 
breast cancer cells with self-renewal and differentiation properties and high tumorigenic 
activity were ALDH+.48 They were able to xenotransplant ALDH+ cells from human breast 
cancer tumors into NOD/SCID mice and consecutively passaged them in vivo, whereas 
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ALDH- cells were unable to do so.48 Cells with ALDH activity isolated from normal human 
breast contain mammary stem cells. Tumors induced by ALDH+ cells show some 
phenotypic and functional characteristics similar to the original tumor, as well as tumor 
size and latent period correspond to the number of ALDH+ cells xenotransplanted. The 
combination of ALDH+ and CD44+/CD24-/low phenotypes appeared to be highly enriched 
in tumorigenic capability with the ability to generate tumors from as few as 20 cells.48  
Since BCSCs have the ability to self-renew and the potential to differentiate, they 
can generate cells with a variety of phenotypes within tumors.35 Several pathways have 
been implicated in the regulation of BCSC self-renewal, including Notch, Hedgehog, and 
Wnt pathways.35 Furthermore, key transcription factors play an important role in regulating 
BCSCs include NF-κB, c-Jun, Forkhead-like-protein Dach1, and CDK inhibitor 
p21CIP1.35 Indeed, in vitro and in vivo evidence revealed the importance of PTEN/PI3-
K/Akt/Wnt/β-catenin pathway in BCSCs biology. For instance, knocking-down PTEN in 
breast cancer cell lines induced activation of Akt and increased mammosphere formation 
and the ALDH+ population.49 By xenotransplanting these cells into NOD/SCID mice, it 
increased Akt phosphorylation and tumorigenicity, which indicates that Akt is involved in 
regulating BCSCs expansion by activating the Akt phosphorylates GSK3β and thereby the 
Wnt pathway.49 In addition, BCSCs self-renewal maintenance was shown to be regulated 
by the ongoing autocrine signaling via the Wnt pathway.50 
Another important feature of BCSCs is their ability to differentiate into non-stem 
breast cancer cells.48 Indeed, retinoic acid, which is oxidized from retinol by ALDH, plays 
a role in the control of self-renewal vs. differentiation of BCSCs.51 ATRA, an inducer of 
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retinoid signaling, decreases mammosphere formation and either induces genes expressed 
in differentiated breast cancer cells or dowregulates several programs involved in BCSCs 
self-renewal such as the polycomb EZH2 network, Wnt signaling, and Akt/β-catenin 
signaling.48 These findings suggest that ALDH activity and retinoid signaling regulates the 
BCSCs population by promoting differentiation and highlights the possible therapeutic 
application of compounds such as ATRA or others that force the differentiation of 
BCSCs.35 
2.4 Potential Markers of Aggressive Breast Cancer Stem Cells 
TNBC, lacking ER and PR expression and HER-2 amplification, poses several 
therapeutic challenges because of the diversity and heterogeneity of the disease and the 
absence of distinct molecular targets.5 Characteristically, TNBC tumors are apparently 
larger in size and biologically more aggressive than other breast tumors.25 TNBCs represent 
about 20% of all breast cancers, which more likely affect younger women, and prevalently 
diagnosed in African-American women compared to Caucasian women.25 TNBC patients 
have a poorer prognosis and high rates of metastasis, relapse, and distant recurrence than 
patients with other breast cancer subtypes.26 The 5-years survival rate in metastatic TNBC 
patients is less than 30%, and almost all patients die of their disease regardless of 
chemotherapy regimen, which is the first-line therapy for treatment of TNBC tumors.27 
Therefore, efforts should be focused on targeting molecular markers involved in the disease 
recurrence and poor prognosis to achieve a better treatment with increased efficacy and 
low toxicity. 
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One of the first perception in TNBCs was the remark that they are likely to develop 
in BRCA1 mutation carriers and have gene expression profile matching those of BRCA1-
deficient tumors.52 BRCA1 has a critical role in DNA double strand break repair, which 
involves in the stability of DNA.53 Also, for proper processing and repair of DNA breaks, 
poly ADP-ribose polymerase (PARP) enzymes are essential in repairing DNA damage and 
maintain genomic stability.54 For instance, clinical trials in TNBC using DNA-damaging 
agents and PARP inhibitors show promising result in BRCA1 mutated tumors.55 Other 
identified molecular markers; such as such as VEGF, EGFR, NF-κB, mTOR, and NRF-1 
contributed to the design of targeted therapeutic strategy investigating potential therapies 
for BCSC. 
2.4.1 A potential role for BRCA1 in breast cancer stem cells 
BRCA1 is an important susceptibility gene for breast cancer, which accords 
substantial risks of breast cancer, mainly in the pre-menopausal age group. Classically, 
BRCA1 mutation carriers develop breast tumors that grow rapidly and are high grade and 
estrogen receptor negative.52 Indeed, biological and molecular features of human BRCA1 
mutation carriers suggest that one of the key functions of this gene is to act as a stem cell 
regulator.56 BRCA1 is considered as a link between breast development and breast cancer, 
and mutations within this gene may significantly alter both processes.56 Additionally, 
several studies have demonstrated that BRCA1 plays a critical role in mammary 
differentiation of stem cells.57–59 Indeed, knocking-down BRCA1 in primary breast 
epithelial cells causes an increase in cells exhibiting the stem cell marker ALDH1.60 It is 
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suggested that damage and/or loss of BRCA1 may cause an increase in genetically unstable 
breast stem cells.60 
BRCA1 is important for DNA double-strand break repair by homologous 
recombination, and significant mutations in this gene may contribute to tumorigenesis of 
breast cancer.61 In addition, PARP is one of the enzymes involved in base excision repair, 
a major pathway in the repair of DNA single-strand breaks.54 Indeed, BRCA1 dysfunction 
overwhelmingly signals cells to inhibit PARP enzymatic activity, which leads to the 
accumulation of DNA lesions.  This eventually causes chromosomal instability, cell cycle 
arrest, and consequent apoptosis.62 Thus, the targeted inhibition of specific DNA repair 
pathways, using PARP inhibitors, in aggressive breast cancer stem cells may allow the 
design of specific and less toxic therapies for BRCA1-mutant breast tumors. 
2.4.2 A potential role for VEGF in breast cancer stem cells 
Angiogenesis plays an essential role in the development, invasion, and metastasis 
of aggressive metastatic cancers, such as TNBC.63 There are multiple angiogenic factors 
commonly overexpressed by aggressive and invasive breast cancers, such as vascular 
endothelial growth factor (VEGF).64 VEGF is considered the most potent endothelial cell 
mitogen and a regulator of vascular permeability.63 Several retrospective studies 
significantly associated VEGF levels with overall survival of patients with early stage 
breast cancer. Tumors with elevated levels of VEGF have a higher risk of recurrence than 
low-angiogenic tumors.63 Nakopoulou et al. reported that aggressive breast cancer tissue 
strongly overexpresses VEGF receptors, specifically VEGFR-2.65  Recently, VEGF, in 
addition to angiogenic effects, has been shown to possibly drive BCSC self-renewal via 
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VEGFR-2 and increase ALDH activity in TNBC.66 Wang et al. suggested that VEGF could 
be an indicator of malignant transformation, tumorigenesis and progression of aggressive 
breast cancer stem cells; which usually associated with tumor differentiation.67 Therefore, 
the targeted inhibition of angiogenesis, using anti-VEGF treatment, may improve the 
efficacy of therapeutic strategy against BCSC. 
2.4.3 A potential role for EGFR in breast cancer stem cells    
Epidermal growth factor receptor (EGFR) expression has been linked to breast 
cancer, with overexpression in more than 50% of TNBC tumors.68 Even though EGFR 
amplification is rare in invasive breast cancer, TNBC tumors have a rather high frequency 
of EGFR amplification, approximately 25% of TNBC cases.69 A common variant of EGFR, 
EGFR variant III, is a naturally occurring deletion mutant of the EGFR and predominantly 
active variant initially identified in a high percentage of glioblastoma multiforme brain 
tumors.70 However, Del Vecchio et al. found that EGFR variant III is expressed in 
aggressive breast tumors and interestingly involved in the stem cells self-renewal pathway, 
through the Wnt pathway, of this aggressive breast cancer.71 Moreover, a recent study has 
found a significant positive correlation between EGFR and tumor stem cell markers 
CD44/CD24 expression in patients with aggressive breast cancer.72 Together, these 
findings suggest that EGFR could be a promising prognostic biomarker for TNBC. In 
addition, EGFR-targeted therapy, using anti-EGFR-based treatment, might have a 
promising therapeutic significance in TNBC. 
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2.4.4 A potential role for NF-κB in breast cancer stem cells 
A common feature established in most breast cancer tumors is the essential 
activation of NF-κB, a family of transcription factors that play critical roles in cell survival, 
proliferation, inflammation and immunity, together with the initiation and progression of 
breast cancer.73 Indeed, the binding of epidermal growth factor (EGF) to its receptor 
(EGFR) also ultimately activates NF-κB and most likely contributes to the enhanced 
activity of this transcription factor in aggressive breast cancer cells.74 Moreover, NF-κB 
regulates the expression of anti-apoptotic genes and activates different pro-inflammatory 
cytokines and chemokines, which is a key molecular link between inflammation and 
oncogenesis initiation and progression.74 In addition, an interesting study has shown that a 
temporary activation of the kinase onco-protein Src in normal breast cells have resulted in 
phenotypic transformation that includes the formation of multiple foci, which has the 
ability to form colonies in soft agar and tumors in xenografts as well as mammosphere 
formation.75 This epigenetic switch, defined when a stable cell type changes into another 
stable cell type without any modification in DNA sequences, involves a rapid inflammation 
response that requires NF-κB.75 This distinct finding confirms the key role NF-κB plays in 
the self-renewal capability of aggressive BCSCs, as demonstrated by Src, an oncogenic 
kinase that promotes the development of BCSCs and the well-defined role of NF-κB in this 
process. Thus, NF-κB seems to be a critical molecular marker for aggressive BCSCs, and 
an interesting potential target in the treatment of aggressive breast tumors. 
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2.4.5 A potential role for mTOR in breast cancer stem cells  
Mammalian target of rapamycin (mTOR) kinase mainly controls G1 cell cycle 
protein synthesis, preceding cell replication.76 It is a member of the PIKK-related kinase 
family, which regulates signal transduction paths linking proliferative stimuli with cell 
cycle progression and also mediated PI3K/AKT signaling pathway, potentially overactive 
in a variety of breast cancer settings.77 A recent study has found that TNBCs exhibited a 
significant decrease in oxygen consumption and a substantial increase in glucose uptake 
and lactate production compared to receptor-positive cells.78 It also showed that the mTOR 
pathway is important in regulating oxidative phosphorylation in breast cancer cells and 
manipulation of expression of this key molecule could significantly alter mitochondrial 
respiration and glucose metabolism.78 Indeed, the PI3K/mTOR signaling pathway plays a 
significant role in cancer stem cells. For instance, activation of the PI3K/mTOR pathway 
in adult blood cells through phosphatase and tensin homolog (PTEN) serves as a negative 
regulator of mTOR; deletion led to the generation of leukemia-initiating cells.79 More 
importantly, activation of PI3K/mTOR signaling, by knocking down PTEN, increased 
BCSCs.49 Therefore, these findings suggest that mTOR could be a possible marker for 
TNBC and selectively targeted for inhibiting cancer stem cells for improved treatment of 
aggressive breast cancer. 
2.4.6 A potential role for NRF1 in stem cells 
Nuclear respiratory factor 1 (NRF1) plays an important role as a regulator of cell 
cycle genes. NRF1 binding site has been identified by comparing genome-wide locations 
in genes involved in DNA replication, mitosis, and cytokinesis.80 Some of the genes which 
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contain NRF1 binding sites on their promoters include Cdc2, guanine-nucleotide exchange 
factor, RCC1, DNA polymerase-α, ornithine decarboxylase, GADD153, growth-arrest and 
DNA-damage-inducible protein153.80 Mammary carcinogenesis is characterized by an 
increased expression of NRF1, which may be linked, with increased energy demand by 
rapidly proliferating cells.81 However, NRF1's role in breast carcinogenesis may be more 
than mere energy modulators.81 NRF1 has been reported to be over-expressed in a number 
of malignant tissues including breast cancer tissues where its levels are higher in disease 
regions compared to adjacent normal tissue or unaffected regions suggesting that NRF1 
may play a role in breast carcinogenesis.82 NRF1 may also play major roles in modulating 
cell proliferation in a manner not related to mitochondria biogenesis.83 Up-regulating the 
expression of key regulators of mitochondrial biogenesis, such as a peroxisome 
proliferator-activated receptor γ, coactivator 1α (PGC-1α) and the transcription factor 
NRF1 shifts the metabolism to oxidation and suppresses fatty acid biosynthesis by energy 
homeostasis modulator in TNBCs.84 A recent report has identified a regulatory branch of 
the mitochondrial unfolded protein response (UPRmt), which is mediated by the interplay 
of SIRT7, a histone deacetylase, and NRF1 are coupled to cellular energy metabolism and 
proliferation.85 NRF1 knockdown reduces SIRT7 expression and occupancy. While 
inactivation of SIRT7 causes increased mitochondrial protein folding stress, and 
compromised regenerative capacity of hematopoietic stem cells.85 
Most studies on the control of mitochondrial gene expression implicate PGC-1α as 
a “master controller” of mitochondrial biogenesis, co-activating PPARα and NRF-1.86 An 
interesting study has induced the expression of PGC-1α, PPARα, and NRF-1 during 
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cardiomyocyte differentiation of murine stem cells and found that the application of 
cardiomyocyte differentiation inducer has increased the expression of PGC-1α, PPARα, 
and NRF-1 coincidently in early differentiation and the increase was dose-dependently up-
regulated by the inducer.87 The parallel increase in NRF-1 ensured the coordinate induction 
of mtDNA transcription and replication, subsequently leading to the enhanced expression 
of mitochondrial proteins that are vital for respiratory chain function.88 Also, the elevation 
of PGC-1α, PPARα, and NRF-1 due to the phosphorylation of the p38 MAPK, stimulated 
by the inducer, has a significant part in the mechanisms of the murine embryonic stem cells 
cardiac differentiation.87 Altogether, NRF1 could be a novel molecular marker for stem 
cell targeting and more specifically an interesting molecular signature for TNBC stem cells. 
Clearly, there is a major need to develop effective treatment based on molecular 
markers of TNBC by understanding the molecular basis of this aggressive type of breast 
cancer. To understand the complexity of the disease and identify the molecular markers 
that can be potentially targeted for therapy, more extensive biological, molecular, and 
genomic analysis are necessary. To provide a great perception on the heterogeneity of this 
disease and provide platforms on preclinical effective treatment development, we need to 
identify the diverse subtypes of TNBC and their molecular modulators in corresponding 
physiological mechanisms. 
2.5 Mitochondria in Cancer and Cancer Stem Cells: A Promising Target for 
Therapy 
Mitochondria are double membraned, made of phospholipid double layers and 
proteins, organelles that considered to be the main generators of ATP, metabolites for the 
26 
 
construction of macromolecules and reactive oxygen species (ROS).89 Beside their role as 
the powerhouses of the cell, they also play a critical role in calcium homeostasis, redox 
signaling and cell fates.89 Specific metabolic activities can contribute to the initiation and 
progression of tumor growth. (Figure 2.5.1).89 For instance, several cancer cells are 
characterized by their dysfunctional mitochondria, which demonstrated by the 
transformation of energy metabolism from oxidative phosphorylation to active glycolysis 
and increased generation of ROS. These metabolic changes, are often associated with 
upregulation of NADPH oxidase, result in oxidative burst which characterized by the rapid 
production and release of ROS.89 Importantly, mechanisms involved in cancer cell 
metabolic reprogramming are associated with oncogenic signals, which has recently 
attracted attention of multiple basic research and clinical oncology investigations on 
targeting mitochondria as a cancer therapeutic strategy.90 The transformation of CSCs into 
a differentiated tumor is a multifactorial process which includes metabolic changes in 
energy conversion with increased expression of genes involved in glycolysis and alteration 
in Krebs’s cycle flux.91 As stem cells show a preference for anaerobic metabolism, it has 
been established that cancer cells activate glycolytic signal pathways for energy supply and 
support the connection between energy remodeling and mitochondrial apoptosis resistant.92 
These metabolic features probably reveal some similarities between CSCs and 
differentiated cancer cells, with mitochondria having a key role in the maintenance of self-
renewal and stemness.93 Since, mitochondria are the cell principal site of energy 
metabolism, the main source of ATP, and are critically involved in apoptotic cell death, 
mitochondrial dysfunction significantly disrupts normal cellular activities, which is a 
feature of several tumor characteristics.94 Recent hypothesis suggest that altered function 
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Figure 2.5.1 Types of Mitochondrial Dysfunction in Cancer Cells. Types of mitochondrial 
dysfunction include A) defective respiration which cause reduced oxygen consumption and 
increased ROS production; B) mtDNA mutations are frequently identified in cancer tissues and 
have a high potential to result in mitochondrial dysfunction and contribute to tumorigenesis; C) 
decreased mtDNA copy number, frequently detected in cancer tissues, is expected to affect energy 
production and increase ROS generation and cell survival, processes which are involved in cancer 
progression; and D) defects in the mitochondrial enzymes may result in deregulation of cellular 
energetics in cancer cells, which includes several enzymes of the TCA cycle such as Succinate 
dehydrogenase (SDH), Fumarate hydratase (FH), and Isocitrate dehydrogenase (IDH).95  
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of mitochondria in tumors plays an active role during disease development and 
progression.96 Moreover, tumor cells and stem cells have a common ability to 
uncontrollably self-reproduce and possess an increased dependency on glycolysis for ATP 
production.97 Proliferating tumor cells adapt to aerobic glycolysis whereas stem cells 
suppress their metabolism for maintaining their functionality.97 Accordingly, glycolytic 
metabolism could be a therapeutic target through reversal of the abnormal metabolism of 
cancer cells by shifting it from glycolysis to glucose oxidation using dichloroacetate 
(DCA), a mitochondria-targeting small molecule. Indeed, DCA is reported to inhibit 
proliferation, induce apoptosis and suppress tumor growth by normalizing mitochondrial 
function.98 Also, DCA was shown, for putative CD133+ glioblastoma stem cells, to prevent 
cancer initiating cells by inhibiting their mitochondrial activity.99 
There are numerous molecules currently being tested in clinical trials that act on 
mitochondria. For instance, several clinically approved anticancer drugs such as paclitaxel, 
VP-16 (etoposide) and vinorelbine, as well as an increasing number of experimental 
anticancer drugs such as, ceramide, MKT077 and CD437, lonidamine, betulinic acid have 
been found to act directly on mitochondria to trigger apoptosis.100 As these potential drugs 
usually do not exhibit adequate tumor and mitochondria-specific accumulation, an 
intensive effort to develop tumor-targeted mitochondria-specific approaches could be a 
significant help towards developing mitochondrial targets for cancer therapy. The selective 
accumulation approach to targeting tumor mitochondria requires two levels of specific 
accumulation; drug accumulation in the tumor and then drug accumulation in the 
mitochondria of cancer cells.101 Conjugation of, one of the most commonly used 
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mitochondrotropic molecules, TPP cation has been used to deliver various bioactive cargos 
to mitochondria including antioxidants like coenzyme Q, ubiquinone, and various 
nitroxides, and also nucleic acids peptide and Cyclosporin A, which indicate the broad 
applicability of such an approach to mitochondria-specific delivery (Figure 2.5.2).102 Also, 
TPP has been used in mitochondrial targeted photodynamic therapy to selectively target 
and inhibit Hsp90 activity in mitochondria of human cancer cells.103 Overall, the possibility 
to have a ligand that can mediate both tumor-specific delivery and mitochondria-specific 
delivery inside the tumor cells is still in question. This could be attainable using a tumor-
specific and mitochondria-specific nanocarrier to deliver an active molecule to 
mitochondria. The development of nanocarrier-based approaches becomes an integral part 
of mitochondria-targeted approaches to cancer therapy. Modified mitochondria-targeted 
nanocarriers are not only effective in the tumor-specific accumulation of a drug but also 
mediate mitochondria-specific accumulation within a tumor cell, which make them the 
ultimate tool in mitochondria-targeted anticancer approaches. 
2.6 Potential Nano-therapy for Breast Cancer  
2.6.1 Biological application and characterization of nanoparticles 
The rapid developing field of nanotechnology including the biological application of 
nanoparticles have given rise to new diagnostic and therapeutic possibilities in the 
treatment of various cancer types. Recently, the use of conjugated nanoparticles allowed at 
least ten cancer-related proteins to be detected on tiny tumor sections, providing a new 
technique of analyzing the proteome of a distinct tumor, which potentially can increase the 
diagnosis and therapeutic efficacy.104 Ultimately, the use of nanoparticles allows  
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Figure 2.5.2 TPP Cation Accumulation in Mitochondria. The uptake of TPP cation into the 
cytoplasm (5-10 fold) is due to the negative plasma membrane potential (ΔΨp). Further 
accumulation of TPP from the cytoplasm into mitochondria (100-500 fold) is driven by the highly 
negative mitochondrial membrane potential (ΔΨm).   
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immediate tumor targeting and drug delivery in a unique fashion. Indeed, nanoparticles 
developed for drug delivery have many designs in terms of size, shape, and materials. Their 
characteristics usually differ in term of drug stability, loading capacity, release rate, and 
targeted delivery capability (Table 2.6.1.1).104 
2.6.2 Targeting breast cancer using nanoparticles/nanocarriers 
Nanomedicine focuses on application of nanotechnology in medicine for diagnosis, 
prevention, detection, and treatment of the disease. Targeted drug delivery system offers 
many potential benefits such as: (i) avoiding the side effects of the clinical formulation for 
improving solubility, (ii) protecting the entrapped therapeutic drug from degradation, (iii) 
modifying pharmacokinetic and tissue distribution profile to increase drug distribution in 
tumor, (iv) reducing toxicity to normal cells, and (v) increasing cellular uptake and 
internalization in cancer cells.23 Moreover, besides use as drug delivery systems for cancer 
therapy, nanoparticles loaded with imaging agents were also found useful in imaging for 
tumor diagnosis. 
2.6.2.1 Imaging and diagnosis of BC using nanoparticles/nanocarriers 
Although magnetic resonance imaging (MRI) is considered very sensitive in 
detecting small tumors, its relative specificity tends to be low due to false positive 
signals.105 The development of MRI contrast agents that are molecularly targeted may 
result in increased image specificity and clinical advantage. To this end there have been 
several studies that have targeted nanoparticles to breast cancer for enhanced breast cancer 
imaging.105 Indeed, an interesting study has conjugated the amino terminal fragment of 
urokinase-type plasminogen activator (uPA) to magnetic iron oxide nanoparticles and  
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Nanoparticles Shapes Characteristics 
Dendrimers 
• Branched treelike. 
 
 
• Multifunctional central core.  
• Drug molecules attached to 
functional groups on the 
dendrimer surface.106  
• Host both hydrophobic and 
hydrophilic. 
• Useful delivery agents for 
genes and anticancer 
agents.104  
Micelles 
• Spherical or globular structures. 
 
 
• Form when constituent 
molecules with a 
hydrophobic end clump to 
form the central core.  
• Liquid environment. 
• Useful for delivery of water 
insoluble drugs carried in the 
hydrophobic central core.106 
Nanospheres 
• Spherical structures. 
 
 
 
• Composed of matrix system  
• Drug distributed by 
entrapment, attachment, or 
encapsulation.  
• Surface can be modified by 
the addition of polymers and 
biological materials. 
•  Ligands or antibodies may 
be attached for targeting 
purposes.107 
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Nanocapsules 
• Vesicular systems. 
 
 
• Central cavity or core to 
which drug confined.  
• Core is surrounded by an 
outer shell polymeric 
membrane to which surface 
bound targeting ligands or 
antibodies may be attached.  
• Core material may be solids, 
liquids, or gas. 
• Core environment may be 
aqueous or oily.107 
 
Fullerenes & 
Nanotubes 
• Hollow sphere or ellipsoid tube. 
 
 
• Composed of carbon atoms. 
• Atoms trapped inside 
fullerenes and tubes and 
antibodies or ligands bound 
to the surface for 
targeting.108 
Liposomes 
• Vesicles structure. 
 
 
• Composed of lipid layers.104 
Liposomes can disintegrate 
by electrostatic, 
hydrophobic, and van der 
Waals forces. 
• Coating particles with inert 
polymers (PEG) for steric 
stabilization.109 
• Surface coating allow 
liposomes to circulate for 
several days without 
clearance. 
• Liposomal vesicles release 
drug at the cell membrane 
and can access tumor cells at 
high concentrations. 
• This strategy reduces toxic 
side effects to normal tissue, 
while enhancing the 
therapeutic index of the 
delivered drug.104 
 
Table 2.6.1.1. Nanoparticles Sizes, Shapes, and Materials. 
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demonstrated binding and internalization of these nanoparticles by uPA receptor 
expressing tumor cells.110 Controlled delivery of the nanoparticles into mice bearing 
mammary tumors led to accumulation of particles in tumors and the generation of magnetic 
resonance contrast images that were detectable by a clinical MRI scanner.110 Other 
strategies for enhanced MRI signals have included the use of folate receptor targeted 
magnetic oxide nanoparticles.111 
Gold nanoshells (silica core surrounded by a thin gold shell) can be optically tuned 
with resonance that spans the visible and infrared spectrum.112 By placing the peak 
absorption properties in the near infrared (NIR) region where tissue absorption is at 
minimum, nanoshells within tissue can preferentially absorb NIR light energy. 
Photothermal cancer therapy using nanoshell can be achieved by (i) the accumulation of 
nanoshells in the tumor and then (ii) the generation of heat from particle absorption of NIR 
light, which will eventually lead to tumor destruction. Utilizing a targeting strategy of 
conjugation of HER-2 antibody to NIR absorbing nanoshells, investigators have shown 
photothermal destruction of breast cancer cells.113 In addition, in a mouse model, nanoshell 
treated tumors completely regressed after NIR illumination.114 In an effort to further exploit 
the advantages of nanoparticles, investigators have demonstrated the in vivo ability to 
introduce multiple diagnostic capabilities in photothermal therapeutic nanocomplexes by 
simultaneously enhancing both NIR fluorescence and magnetic resonance imaging.115 
These multimodal nanoparticles have been conjugated to HER-2 antibodies and been 
shown to specifically, although not exclusively, accumulate in HER-2-positive breast 
tumors in vivo.115 
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2.6.2.2 Targeted drug delivery system 
Lipid-based nanoparticles have attracted great attention as a drug delivery system 
due to their attractive biological properties such as good biocompatibility, biodegradability, 
low immunogenicity, and the ability to deliver hydrophilic and hydrophobic drugs. Indeed, 
liposomes are the most widely used and studied examples, with bilayer membrane 
structures composed of phospholipids for stabilizing drugs, directing their cargo toward 
specific sites, and for overcoming barriers to cellular uptake.116 PEGylated lipids in the 
liposomes was developed to protect liposomes from destruction by the reticuloendothelial 
system (RES), thus to increase circulation time and increase drug accumulation in the 
tumors. Moreover, Doxil/caelyx, a PEGylated liposome formulation of the anticancer drug 
doxorubicin (DOX), was the first formulation approved for application in the clinic.117 
Targeted lipid-coated nanogels drug delivery platform can: (i) encapsulate a wide range of 
drug chemotherapeutics, (ii) display targeting ligands, and (iii) enhance drug retention 
within the nanogel core after photo-crosslinking and (iv) retain therapeutic activity after 
lyophilization allowing for long term storage.118 Integrin αvβ3-targeted lipid-coated 
nanogels with cross-linked human serum albumin in the core were used for carrying 
various cargoes including paclitaxel, docetaxel, bortezomib, sorafenib and sunitinib. These 
particles exhibited potent activity in tumor cell viability assays with different drugs.118 
Although the work on modification of liposomes has achieved great progress, the 
application of liposomes in the clinic still poses several challenges including rapid 
clearance from the bloodstream, instability of the carrier, high production cost, and fast 
oxidation of some phospholipids. 
36 
 
Polymer-based nanoparticles show enormous potential for treating disease or 
repairing damaged tissues especially for cancer treatment, which relies on their remarkable 
properties including small size, excellent biocompatibility and biodegradability, prolonged 
circulation time in the bloodstream, enhanced drug loading capacity, and easy chemical 
modification or surface functionalization.23 In general, polymer-based nanomedicine can 
be categorized into three groups based on drug-incorporation mechanisms including: 
polymer-drug conjugates by covalent conjugation, polymeric micelles by hydrophobic 
interactions, and polymersomes by encapsulation. Most of the polymers; such as 
poly(lactide), copolymer poly(lactide-co-glycolide), and PEG, are approved by the FDA 
as commonly explored carriers for targeted drug delivery.23  
Protein-based nanomedicine has been given serious attention due to their 
biocompatibility, biodegradability as well as enhanced efficacy and low toxicity during 
treatment. Indeed, protein-based nanomedicine usually consists of natural protein subunits 
of the same protein or the combination of natural or synthetic proteins, and different types 
of drug molecules. There are a variety of proteins used drug delivery systems such as plant-
derived viral capsids, small heat shock protein cages, albumin, soy and whey protein, 
casein, collagen and the ferritin/apoferritin protein cage.119 Albumin may be used as a 
multipurpose protein carrier for improving drug targeting and pharmacokinetic 
properties.120 As such, it is playing a vital role in the development of protein-based 
nanoparticles.120 It demonstrates important features of stability in a broad range of pH (4-
9) and temperature (4 °C - 60 °C), preferential uptake by the tumor, and is non-toxic. 
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Methotrexate-albumin conjugate, albumin-binding prodrug of DOX, and albumin PTX 
nanoparticle (Abraxane) have been designed and are currently in clinical trials.120 
2.7 Conclusion 
The BCSCs concept of self-renewal, pluripotency and tumorigenicity suggests the 
existence of small population of CSCs with increased tumor-initiating ability, tumor 
relapse, metastasis, and resistance to therapies. An interesting connection between CSCs 
and mitochondria prevails, as mitochondrial dysfunction apoptosis is reported to be 
associated with tumor resistance in conventional chemotherapy.93,121 Considering the 
biology, molecular characteristics, and mechanisms of the tumor may help reaching a better 
treatment with increased efficacy and low toxicity. Therefore, therapy targeting 
mitochondria and specific CSCs signaling pathway may trigger cell death signaling 
cascades, mitochondria-dependent apoptosis, and reach total CSCs and tumor elimination. 
The complex nature of CSCs features and mitochondrial functions, including 
signaling pathways and microenvironment, give rise to challenges in selecting the targeted 
element and whether individual or multiple targeting strategies should be used. In this 
regard, nanoparticle-based therapy, using nanoparticles/nanocarriers, seems to have the 
ability to combine various bioactive molecules, specifically, and safely reaching tumor foci 
with enhanced efficacy and low toxicity. The development of effective nanoparticle-based 
therapy for BCSC needs to be optimized through nanoparticles modeling combined with 
experimental validation for ultimate efficiency. The possibility of achieving this goal is 
still a hypothesis and further investigation is needed in this field. 
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CHAPTER 3 
INFLUENCE OF ESTROGEN ON MITOCHONDRIA IN ESTROGEN-
DEPENDENT BREAST CANCER 
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3.1 Abstract 
17 β-estradiol (E2) is a major risk factor for the development of breast cancer. Estrogen, 
through increasing mitochondria-derived reactive oxygen species (ROS), contributes to 
estrogen-induced breast carcinogenesis. However, the exact mitochondrial mechanisms 
underlying the estrogen carcinogenic effect in breast tissue are unknown. The aim of this 
study was to elucidate the mechanisms by which mitochondria contribute to the growth of 
breast cancer. Triphenylphosphonium (TPP), a lipophilic cation whose selective 
accumulation in the mitochondria is driven by both plasma and mitochondrial membrane 
potentials, was used in this study to check whether an imbalance in mitochondrial 
bioenergetics, in part, may be responsible for estrogen-induced growth of breast cancer. 
TPP has been shown to rapidly accumulate and be retained by MCF-7 cells, and inhibit 
oxidative phosphorylation in mitochondria. In principle, factors other than membrane 
potential may also play a role to counteract estrogen effects on the growth of breast cancer 
cells. Our results showed that TPP inhibited E2-induced increase of cell viability, growth, 
proliferation, ROS formation, and mitochondrial membrane potential of serum deprived 
estrogen-dependent MCF-7 breast cancer cells. Our results also demonstrated that TPP 
decreased E2-induced DNA damage and mitochondrial ROS production in MCF-7 cells. 
Although demonstrated in a breast cancer cell line, these results indicate that E2 modifies 
mitochondrial dynamics, biogenesis and metabolism, and thus compromises the normal 
development and function of mitochondria in cancer tissues. Furthermore, our findings 
offer a new perspective on the utility of mitochondria-targeted lipophilic cations, such as 
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TPP, as a promising new class of targeted-drugs for the treatment of estrogen-dependent 
breast tumors. 
   
3.2 Introduction 
Estrogens play a major role in the initiation and progression of breast cancer. A large body 
of evidence, both epidemiological and clinical, has linked elevated lifetime exposure to 
estrogens with increased risk of developing breast cancer.1–3 However, the exact 
mechanisms underlying the carcinogenic effect of estrogen in breast tissue are not clearly 
understood. Estrogen receptor (ER)-mediated signaling pathways are considered as the 
most widely acknowledged mechanism of estrogen carcinogenicity.4,5 Whilst, nearly 70% 
of newly diagnosed breast cancer patients are ER+, almost half of those patients do not 
respond to hormonal therapies.6 This suggests that the growth of estrogen-dependent cells 
is regulated not only by ER-mediated signaling pathways, but also by ER-independent 
pathways.7 
Mitochondria play a central role in cellular metabolism, calcium homeostasis, 
redox signaling, apoptosis and cell death.8 Over the past decade, there has been extensive 
investigation into the role of mitochondria in regulating cell growth and proliferation.8 
Tumor cells are characterized by dysfunctional mitochondria, which is demonstrated by 
the transition of the source of metabolic energy from oxidative phosphorylation to active 
glycolysis and increased ROS production.9 Estrogens, through increasing mitochondria-
derived ROS, contribute to breast carcinogenesis, although the exact role of mitochondria 
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and ROS in the carcinogenic effect of estrogen in breast tissue is still extensively 
unexplored.10 For instance, 17 β-estradiol (E2), the most potent endogenous estrogen, 
induces DNA synthesis in MCF-7 breast cancer cells through mitochondrial oxidant 
signaling.10 Indeed, E2-induced mitochondrial ROS regulates cell cycle G1 to S transition 
via a nongenomic, ER-independent signaling pathway.10 Therefore, targeting mitochondria 
as a cancer therapeutic strategy has attracted attention in recent years and multiple 
investigations and studies in this area have been conducted.9 For instance, several studies 
have targeted mitochondria and mitochondria-associated molecules and pathways, 
including mitochondrial membrane potential, electron transport chain, and apoptotic 
pathway, as a potential cancer therapeutic targets.9 
To achieve optimal targeting of therapeutic agents, tumor- and mitochondria-
specific accumulation is necessary.11 The Triphenylphosphonium (TPP) cation has been 
used to deliver various bioactive molecules to mitochondria including antioxidants, which 
indicates the broad applicability of such an approach to mitochondria-specific delivery.12 
TPP is a lipophilic cation that has the property of being lipid-soluble, even with its net 
positive charge. This property allows TPP to pass through the phospholipid bilayers of the 
cell membrane and mitochondria.13 TPP conjugated to a therapeutic molecule will 
accumulate in the cytoplasm, about 5 to 10 fold compared to the extracellular environment, 
due to the driving force of the plasma membrane potential (ΔΨp, -30 to -60 mV).13 Further 
accumulation of TPP conjugates, about 100 to 500 fold compared to the extracellular 
environment, is driven by the mitochondrial membrane potential (ΔΨm, approximately -
180 mV).13 However, TPP has been shown to produce an uncoupling effect.14 Indeed, 
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cellular toxicity linked to TPP cation may limit its therapeutic potential.15 For instance, 
TPP accumulation in the mitochondria is capable of disrupting its membrane integrity and 
altering the metabolic activities such as ATP synthesis and respiratory chain functions.16 
Moreover, TPP cation has shown to potentially affect mitochondrial bioenergetics by 
increasing proton leak, decreasing mitochondrial membrane potential and inhibiting 
respiratory chain complexes.17 
In order to elucidate the mitochondria-targeted effect of E2 in breast cancer, we 
examined their inhibition by using a mitochondria-targeted agent TPP. We evaluated the 
cell viability, growth, proliferation, mitochondrial membrane potential, cellular ROS 
formation, DNA damage, and mitochondrial ROS production of estrogen-dependent breast 
cancer (MCF-7), metastatic breast cancer (MDA-MB231), and normal breast epithelial 
(MCF-10A) cells treated with E2, TPP, and co-treatment of E2 with TPP, in vitro. 
 
3.3 Materials and methods 
3.3.1 Chemicals and reagents. 
17β-Estradiol (E2), (4-carboxybutyl) triphenylphosphonium bromide (TPP), 
dimethylsulfoxide (DMSO), 3(4,5-dimethylthiazolyl-2)2,5-diphenyl tetrazolium bromide 
(MTT), sulforhodamine B (SRB), trichloroacetic acid (TCA), and H2O2 were all purchased 
from Sigma-Aldrich (St. Louis, MO, USA). A cell proliferation ELISA (BrdU-
colorimetric) kit was obtained from Roche Diagnostics (Indianapolis, IN, USA). MitoSOX 
Red, MitoTracker Green, and propidium iodide (PI) were purchased from Thermo Fisher 
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Scientific (Waltham, MA, USA), I 2′,7′-Dichlorofluorescin diacetate (DCFDA) and all 
tissue culture reagents were purchased from Invitrogen Corporation (Carlsbad, CA, USA), 
unless otherwise specified. 
3.3.2 Cell culture.  
The estrogen-dependent breast cancer (MCF-7), metastatic breast cancer (MDA-MB231), 
and normal breast epithelial (MCF-10A) cells were routinely cultured in phenol red 
DMEM-F12 media (1:1) supplemented with 5% (v/v) fetal bovine serum (FBS), 100 
IU/mL penicillin, and 100 µg/mL streptomycin (complete media) in a humidified 
atmosphere containing 5% CO2 at 37 °C. The cell culture media, serum, and antibiotics 
were purchased from Invitrogen Corp, CA, USA. Culture media were changed to starvation 
media (serum free media + antibiotics) and cells incubated for 48 h prior to commencement 
of all experiments, unless otherwise indicated. 
3.3.3 Cell viability.  
MTT was used to determine cell viability according to the manufacturer's protocol.18 In 
brief, MCF-7, MCF-10A, and MDA-MB231 cells were seeded in three separate 96-well 
plates (approx. 7500 cells/well) overnight in complete media and serum starved for 48 h 
prior to treatment with E2, TPP, and co-treatment of TPP with E2 for 48 h. Then, 20 µL of 
(5 mg/mL) MTT was added to each well. After incubation for 3.5 h at 37 °C, the media 
was carefully removed and 100 µL of MTT solvent (100% DMSO) was added to each well. 
The plates were then covered with aluminium foil and agitated on shaker for 15 min. 
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Absorbance was recorded at 590 nm (reference λ at 620 nm) on a Tecan Genios microplate 
reader. 
3.3.4 Cell growth.  
SRB was used to determine cell growth as described by Skehan et al.19 Briefly, cells were 
seeded in three separate 96-well plates (approx. 7500 cells/well) for 24 h in complete media 
and serum starved for 48 h prior to adding the various cell treatments for 48 h. The cells 
were then fixed with 50% TCA solution, layered on top of the existing medium, and chilled 
to 4 °C. After 1 h of incubation at 4 °C, the plates were rinsed four times with distilled 
water. Then 100 µL of 0.4% (w/v) SRB was added to cover the bottom of the well and 
allowed to stain for 20 min. Unbound dye was removed by four washes with 1% acetic 
acid, and protein-bound dye was extracted with 10 mM unbuffered Tris base [tris 
(hydroxymethyl) aminomethane]. Absorbance was determined at 590 nm (reference λ at 
620 nm) on a Tecan Genios microplate reader. 
3.3.5 Cell proliferation.  
BrdU incorporation assay was used to assess cell proliferation. A colorimetric BrdU cell 
proliferation assay was performed according to the manufacturer's instructions (Roche, 
Indianapolis, IN, USA). The BrdU Cell Proliferation Assay Kit detects BrdU incorporated 
into cellular DNA during cell proliferation using an anti-BrdU antibody, which is an 
indicator of the newly synthesized DNA in proliferating cells or repair of damaged cells.20 
Briefly, MCF-7 cells were grown in 96-well plates until 50% confluent in complete media, 
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and serum starved for 48 h followed by the various cell treatments for 48 h. Absorbance 
was measured by a Tecan Genios microplate reader at 450 nm (reference λ at 700 nm). 
3.3.6 Mitochondrial bioenergetics.  
The rhodamine (Rh123)-mitochondrial membrane potential assay was used to evaluate 
mitochondrial bioenergetics. The Rh123 fluorescent dye distributes according to the 
negative membrane potential across the mitochondrial inner membrane.21 Loss of potential 
will result in loss of the dye and therefore fluorescence.21 In brief, cells were seeded into 
black sided 96-well flat bottom plates (Thermo Fisher Scientific Inc, MA, USA) overnight 
in complete media and serum starved for 48 h prior to adding the various cell treatments 
for 48 h. Followed by an addition of 10 μL of 0.1 μg/mL of Rh123 to each well. The cell 
suspension was gently agitated and incubated at 37 °C for 30 min in the dark. The 
fluorescence of Rh123 was measured on a Tecan Genios microplate reader using 503 nm 
and 527 nm as excitation and emission filters, respectively. 
3.3.7 Cellular ROS production.  
DCFDA was used to determine cellular ROS production as described by Felty et al.22 
Briefly, cells were seeded into black sided 96-well flat bottom plates and allowed to adhere 
overnight. Post seeding, cells were serum starved for 48 h after which they were treated for 
48 h followed by incubation with 10 µM DCFDA for 20 min. The oxidized products were 
measured on a Tecan Genios microplate reader using 485 nm and 535 nm as excitation and 
emission filters respectively. 
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3.3.8 Mitochondrial ROS detection.  
MitoSOX Red mitochondrial superoxide indicator was used to estimate the amount of 
superoxide anion produced in mitochondria. The analysis was performed according to the 
method described by Hahm et al.23 with the use of confocal microscopy and fluorescence 
microplate reader. Briefly, cells were seeded into 96-well plate and allowed to adhere for 
an overnight. Post seeding, cells were serum starved for 48 h after which they were treated 
for 48 h followed by incubation with 5 µM MitoSOX Red for 30 min. Cells were washed 
with phosphate-buffered saline (PBS) and fluorescence was detected using a Gemini EM 
microplate spectrofluorometer (Ex/Em: 510/580 nm). For immunofluorescence staining, 
cells were seeded and treated in chamber slides. After treatment, cells were incubated with 
5 µM MitoSOX Red for 30 min at 37°C. Cells were then incubated with 200 nM 
MitoTracker Green for 15 min, to stain mitochondria. After washing with PBS, cells were 
fixed with 4% paraformaldehyde for 15 min at room temperature (RT) and examined under 
a Nikon C1 laser scanning confocal microscope at 40× objective magnification. 
3.3.9 DNA damage assessment.  
Single cell gel electrophoresis (the comet assay) was used to measure DNA damage as 
described by Karbaschi & Cooke.24 Briefly, cells were seeded into 6-well plates and 
allowed to adhere overnight. Post seeding, cells were treated for 3 h or 24 h, on RT, and 
then processed for alkaline comet assay. In brief, cells were immersed in 0.6% low melting 
point agarose, embedded on pre-coated slides with 1% normal melting point agarose, and 
lysed overnight at 4 °C. The slides were washed and then incubated with alkaline 
electrophoresis solution for 20 min. Subsequently, electrophoresis was carried on in the 
59 
 
same solution for 20 min at 25 V. After electrophoresis, the slides were incubated with 
neutralization buffer (0.4 M Tris-base, pH 7.5) for 20 min, washed and subsequently dried 
and stained with propidium iodide (PI, 2.5 µg/mL) for 20 min. The images of comets were 
visualized by using an on-line CCD camera, fluorescence microscopy at 40× 
magnification, and Comet Assay IV software (Perceptive Instruments, Suffolk, UK). 100 
cells were scored for each treatment and the percentage of tail DNA was calculated for 
each nucleoid image. 
3.3.10 Statistical Analysis.  
Statistical analyses was performed using GraphPad Prism, version 6 (GraphPad, CA, 
USA). The data was evaluated using one-way ANOVA and Tukey's multiple comparisons 
tests to compare the values between groups. The level of statistical significance was set at 
p <0.05. 
 
3.4 Results  
E2-induced cellular viability is inhibited by TPP in estrogen-dependent breast cancer 
cells.  
We initially tested the effect of E2, TPP, and co-treatment of E2 with TPP on the viability 
of MCF-7, MDA-MB231, and MCF-10A cells in serum-free conditions. Cellular viability 
was assessed by MTT assay, which determines mitochondrial activity.25 As shown in 
Figure 3.4.1, a significant increase in cell viability was observed for both E2 100 pg/mL (p 
<0.0001) and E2 100 ng/mL (p <0.0001), compared to control (0.1% DMSO), for MCF-7  
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Figure 3.4.1 E2 increases viability and co-treatment with TPP decreases E2-induced viability 
in MCF-7 cells, determined by the MTT assay. Cell viability for (A) MCF-7; (B) MDA-MB231; 
(C) MCF-10A. Cells were cultured for 24 h in complete media then serum starved for 48 h prior to 
treatment with E2, TPP, or co-treatment of TPP with E2 for 48 h. Results are expressed as mean ± 
S.E.M. of three independent experiments expressed relative to the control (0.1% DMSO) set as 
100% cell viability. ***(p <0.001) and ****(p <0.0001) treatments are significantly different from 
control or corresponding E2 concentrations.  
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cells (Figure 3.4.1A). This increase was not observed for MDA-MB231 (Figure 3.4.1B) 
nor MCF-10A (Figure 3.4.1C) cells. However, neither concentration of TPP (10 µg/mL or 
100 µg/mL) influenced cell viability of MCF-7, MDA-MB213, and MCF-10A cells. 
Interestingly, the results also showed that co-treatment of E2 with TPP had a significant 
decrease in the cell viability of MCF-7 cells. Treatment with 100 pg/mL E2 was 
significantly inhibited, (p <0.001), by co-treatment with 10 µg/mL TPP. This effect was 
more pronounced at the higher concentration of TPP (100 µg/mL, p <0.0001). A higher 
concentration of E2, 100 ng/mL, was also inhibited by co-treatment with 10 µg/mL TPP 
(p <0.01), and a more significant inhibition by co-treatment with 100 µg/mL TPP (p 
<0.0001). The positive control (5% FBS media) showed a significant increase in the cell 
viability for all cell lines (p <0.0001); however, no significant effect was observed in serum 
free media compared to control (Figure 3.4.1.S). The serum-free conditions used in these 
experiments were optimal for observing E2-induced effect on breast cancer cells, since 
serum deprivation synchronizes cells in the G0/G1 phase of the cell cycle.22 These findings 
show that E2 induces cellular viability and that inhibited by treatment with TPP. 
E2-induced cell growth is inhibited by TPP in estrogen-dependent breast cancer cells.  
To confirm the inhibition of MCF-7 cell viability by co-treatment of E2 with TPP, SRB 
assay was used. This detects cellular protein, to determine the cell growth for the three cell 
lines. A significant increase in cell growth was noted for both E2 concentrations (p 
<0.0001) on MCF-7 cell (Figure 3.4.2A). However, this was not noticed for MDA-MB231 
(Figure 3.4.2B) nor MCF-10A (Figure 3.4.2C) cells. Nevertheless, there was no observable 
cell growth effect with either TPP concentrations on the three cell lines (Figure 3.4.2). 
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Figure 3.4.2 E2 increases growth and co-treatment with TPP decreases E2-induced growth 
in MCF-7 cells, determined by SRB assay. Cell growth for (A) MCF-7; (B) MDA-MB231; (C) 
MCF-10A. Cells were cultured for 24 h in complete media then serum starved for 48 h prior to 
treatment with E2, TPP, or co-treatment of TPP with E2 for 48 h. Results are expressed as the mean 
± S.E.M. of three independent experiments expressed relative to the control (0.1% DMSO) set as 
100% cell growth. *(p <0.05) and ****(p <0.0001) treatments are significantly different from 
control or corresponding E2 concentrations.  
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Intriguingly, when E2 was co-treated with TPP, a significant inhibition in cell growth was 
observed for MCF-7 cells. The treatment with 100 pg/mL E2 was inhibited by co-treatment 
with 10 µg/mL TPP (p <0.05), and further significant inhibition by co-treatment with 100 
µg/mL TPP (p <0.0001). Additionally, the higher concentration of E2, 100 ng/mL, was 
significantly inhibited by co-treatment with 10 µg/mL and 100 µg/mL TPP (p <0.0001). 
5% FBS media significantly increased cell growth (p <0.0001), whereas, serum free media 
did not show any effects on cell growth on all cell lines (Figure 3.4.2.S). These results 
demonstrate that E2 induces cell growth and that inhibited by treatment with TPP. 
E2-induced proliferation is decreased by TPP in estrogen-dependent breast cancer 
cells.  
To further confirm the inhibition of MCF-7 cell viability and growth by co-treatment of E2 
with TPP, we tested whether the co-treatment induces a similar effect on cell proliferation 
and DNA synthesis using the BrdU cell proliferation assay, which detects BrdU 
incorporation into cellular DNA during cell proliferation.20 As shown in Figure 3.4.3, both 
E2 concentrations significantly stimulated the proliferation of MCF-7 cells (p <0.0001). 
However, the treatments of both TPP concentration had no effect on the proliferation of 
MCF-7 cells. Interestingly, both co-treatments of E2 with 100 µg/mL TPP significantly 
inhibited E2-induced DNA synthesis and cell proliferation (p <0.05) compared to E2 
concentrations. As expected, 5% FBS media increased cell proliferation and DNA 
synthesis (p <0.0001), while, serum free media did not show any effects on cell 
proliferation for MCF-7 cells. Therefore, our findings show that E2 promotes DNA 
synthesis and cell proliferation and this inhibited by treatment with TPP. 
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Figure 3.4.3 E2 increases DNA synthesis and co-treatment with TPP decreases E2-induced 
DNA synthesis in MCF-7 cells, determined by BrdU cell proliferation assay. MCF-7 cells were 
seeded and grown in 96-well plates until 50% confluent in complete media then serum starved for 
48 h followed by the various treatments for 48 h. Results are expressed as the mean ± S.E.M. of 
three independent experiments expressed relative to the control (0.1% DMSO) set as 100% DNA 
synthesis. **(p <0.01) and ****(p <0.0001) treatments are significantly different from control or 
corresponding E2 concentrations.  
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TPP treatment induces changes in E2-induced mitochondrial bioenergetics in 
estrogen-dependent breast cancer cells.  
Uptake of the lipophilic cation, TPP, has been often used as a membrane potential probe, 
because it is considered to produce an uncoupling effect.14 The possibility that TPP might 
alter E2-induced mitochondrial bioenergetics, via their action at ΔΨm17, was assessed, 
using Rh123-mitochondrial membrane potential assay. As shown in Figure 3.4.4, both E2 
concentrations had significantly increased the Rh123-positive mitochondrial membrane 
potential (p <0.0001) for MCF-7 cells (Figure 3.4.4A). However, this effect was not 
observed in MDA-MB231 (Figure 3.4.4B) or MCF-10A (Figure 3.4.4C) cells. 
Furthermore, treatments with both TPP concentrations did not alter the mitochondrial 
membrane potential for all cell lines. Remarkably, co-treatment of E2 with TPP induces 
loss of ΔΨm of MCF-7 cells. The treatment with 100 pg/mL E2 was significantly reduced 
by the co-treatment with 100 µg/mL TPP (p <0.001), but not with 10 µg/mL TPP. Also, 
the 100 ng/mL E2 was significantly decreased by the co-treatment with 10 µg/mL TPP (p 
<0.01) and 100 µg/mL TPP (p <0.0001), in a dose-dependent manner (Figure 3.4.4A). 
Thus, these findings show that E2 induces an increase in mitochondrial membrane potential 
and this decreased by treatment with TPP in MCF-7 cells. 
E2-induced ROS production is decreased by TPP in estrogen-dependent breast 
cancer cells.  
Since mitochondria are considered a major source of ROS, and treatment with TPP 
decreased E2-induced mitochondrial bioenergetics, cellular ROS production was 
investigated using DCFDA. This assay detects the generation of ROS including:  
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Figure 3.4.4 E2 increases mitochondrial membrane potential and co-treatment with TPP decreases E2-
induced mitochondrial membrane potential in MCF-7 cells, determined by mitochondrial membrane 
potential assay. Rh123-positive ΔΨm for (A) MCF-7; (B) MDA-MB231; (C) MCF-10A. Cells were cultured 
for 24 h in complete media then serum starved for 48 h prior to the various cell treatments for 48 h. Results 
are expressed as the mean ± S.E.M. of three independent experiments expressed relative to the control (0.1% 
DMSO) set as 100% Rh123-positive mitochondria. **(p <0.01), ***(p <0.001), and ****(p <0.0001) 
treatments are significantly different from control or corresponding E2 concentrations.  
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superoxide; hydrogen peroxide; hydroxyl radical and other ROS within the cell.26 As 
shown in Figure 3.4.5, both E2 concentrations, 100 pg/mL and 100 ng/mL, significantly 
increased ROS generation in MCF-7 cells (Figure 3.4.5A). However, both concentrations 
of TPP did not show an effect on ROS production of MCF-7 (Figure 3.4.5A), MDA-
MB213 (Figure 3.4.5B), or MCF-10A (Figure 3.4.5C) cells. Remarkably, co-treatment 
with TPP decreased E2-induced ROS production in MCF-7. Only the higher concentration 
of TPP, 100 µg/mL, was able to significantly decrease the E2-induced ROS production of 
both E2 treatments, 100 pg/mL (p <0.01) and 100 ng/mL (p <0.05), in MCF-7 cells (Figure 
3.4.5A). Thus, these results show that E2 increases ROS production and this could be 
decreased by treatment with TPP. 
E2-induced mitochondrial ROS production is decreased by TPP in estrogen-
dependent breast cancer cells.  
Since the treatment with TPP decreased E2-induced cellular ROS, further investigation 
was needed to localize the source of ROS production. Mitochondrial ROS production was 
detected using MitoSOX Red mitochondrial superoxide indicator, which detects the 
superoxide anion produced in mitochondria. As shown in Figure 3.4.6A, E2 treatment 
caused an increase (p <0.0001) in MitoSOX Red fluorescence in MCF-7 cells compared to 
control (0.1% DMSO). However, TPP did not show an effect on mitochondrial ROS 
production in MCF-7 cells. Astonishingly, co-treatment with TPP decreased E2-induced 
MitoSOX Red fluorescence (p <0.0001). The positive control rotenone, an inhibitor of the 
mitochondrial complex I, showed a significant increase in MitoSOX Red fluorescence (p 
< 0.0001) (Figure 3.4.6A). ROS generation by E2 and TPP treatments in MCF-7 cells was   
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Figure 3.4.5 E2 increases ROS production and co-treatment with TPP decreases E2-induced 
ROS production in MCF-7 cells, determined by DCFDA ROS formation assay. ROS 
production for (A) MCF-7; (B) MDA-MB231; (C) MCF-10A. Cells were cultured for 24 h in 
complete media then serum starved for 48 h prior to treatments for 48 h. Results are expressed as 
the mean ± S.E.M. of three independent experiments expressed relative to the control (0.1% 
DMSO) set as 100% ROS production. *(p <0.05), **(p <0.01), ***(p <0.001), and ****(p <0.0001) 
treatments are significantly different from control or corresponding E2 concentrations.  
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B. 
 
Figure 3.4.6 E2 increases mitochondrial ROS production and co-treatment with TPP 
decreases E2-induced mitochondrial ROS production in MCF-7 cells, determined by 
MitoSOX Red Mitochondrial Superoxide Indicator assay. Cells were cultured for 24 h in 
complete media, serum starved for 48 h prior to treatments for 48 h, and then processed for 
MitoSOX Red assay. (A) Spectrofluorometric analysis for MitoSOX Red fluorescence. Error bars 
represent the mean ± S.E.M. of three individual experiments. *(p <0.05) and **(p <0.01) are 
treatments significantly different from control (0.1% DMSO) or corresponding treatments. (B) 
Representative fluorescence microscopy for MitoSOX Red and MitoTracker Green fluorescence 
in MCF-7 cells (40× magnification). 
71 
 
E2-induced DNA damage is inhibited by TPP in estrogen-dependent breast cancer 
cells.  
Since DNA damage is a naturally expected consequence of cellular metabolism,27 the 
possibility that E2-induced ROS production might increase DNA damage was considered. 
DNA damage was evaluated using the single cell gel electrophoresis (comet assay), which 
measures the percentage of tail DNA as an indicator of DNA damage. As shown in Figure 
3.4.7A, E2 treatment caused an increase in % tail DNA, whereas TPP showed no evident 
effect on % tail DNA in MCF-7 cells. An increase in % tail DNA of E2 and the positive 
control H2O2 over DMSO-treated control was evident as early as 3 h after treatment and 
persisted for at least 24 h (p <0.0001) (Figure 3.4.7A). Intriguingly, co-treatment with TPP 
decreased E2-induced % tail DNA (p <0.0001) for both time periods. Furthermore, co-
treatment of H2O2 with TPP decreased H2O2-induced % tail DNA in MCF-7 cells, in a 
concentration-dependent manner (Figure 3.4.7B). DNA damage by E2 and H2O2 
treatments in MCF-7 cells was confirmed by fluorescence microscopy after staining the 
DNA with PI. As shown in Figure 3.4.7C, DMSO-treated control exhibited no effect on 
the nucleoid body. However, MCF-7 cells treated with 100 ng/mL E2 and 100 µM H2O2 
showed typical comet formations. Interestingly, E2 and H2O2 co-treated with TPP did not 
show any evidence of DNA damage (Figure 3.4.7C). Altogether, these results show that 
E2 and H2O2 induces DNA damage in MCF-7 cells and this could be inhibited by treatment 
with TPP. 
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Figure 3.4.7 E2 increases DNA damage and co-treatment with TPP decreases E2-induced 
DNA damage in MCF-7 cells, determined by the comet assay. Cells were treated with (A) 100 
µg/mL TPP, 100 ng/mL E2, E2 co-treatment with TPP, or 50 µM H2O2, on RT, for 3 h or 24 h; (B) 
100 µg/mL TPP, 50 µM, 100 µM, 150 µM H2O2, or TPP co-treatments with H2O2, on RT, for 3 h; 
and then processed for alkaline comet assay. Error bars represent the mean ± S.E.M. of 300 
determinations from three individual experiments. ****(p <0.0001) treatments are significantly 
different from control (0.1% DMSO) or corresponding E2 or H2O2 concentrations. (C) 
Representative comet formation images of MCF-7 cells for 24 h treatment.  
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3.5 Discussion  
This is the first report of the inhibitory effect of mitochondria-targeted cation, TPP, on E2-
induced responses in MCF-7 cells. Our results demonstrate a profound relationship 
between TPP and E2-induced cellular viability, growth, proliferation, mitochondrial 
bioenergetics, mitochondrial ROS production, and DNA damage suggesting a potential 
contribution of mitochondria in the development of estrogen-dependent breast cancer. 
 Given the ‘classical’ understanding that estrogens induce breast cancer cell 
proliferation and differentiation, and are considered risk factors for breast cancer 
development and progression for estrogen-dependent breast cancer cells, such as MCF-7, 
compared to estrogen independent breast cancer cells, such as MDA-MB231,28 our results 
demonstrated positive relationships between E2 and cell viability, growth, DNA synthesis, 
mitochondrial bioenergetics, ROS production, mitochondrial ROS generation, and DNA 
damage in MCF-7 cells. Indeed, several studies have reported the estrogen-induced growth, 
DNA synthesis and proliferation, ROS production, and DNA damage for several estrogen-
dependent cells.7,22,29–32 In contrast, MDA-MB231 and MCF-10A show no correlation with 
these E2-induced endpoints. 
TPP cation is generally considered biologically ‘inert’ and can slightly, but 
insignificantly, influence mitochondrial metabolism.33 Our results showed that TPP 
concentrations have no notable effect on the three cell lines. However, TPP cation has 
shown to produce an uncoupling effect, which may affect the membrane potential and 
prevent fast production of ROS in mitochondria.33,34. TPP has also been shown to inhibit 
oxidative phosphorylation through inducing a negative effect on the respiratory chain 
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complexes, as well as on mitochondrial membrane potential and ATP synthesis.17 Indeed, 
our data showed profound findings when E2-induced cellular activities are treated with 
TPP. E2 co-treated with TPP, dose-responsively and specifically, reduces mitochondrial 
and cellular activities in MCF-7 cells. E2-induced viability and growth demonstrated a 
remarkable decrease when co-treated with TPP. This suggests that TPP inhibition of E2-
induced viability and growth could be associated with mitochondrial growth signaling and 
biogenesis. Estrogen-induced cell growth has been linked to mitochondrial signaling 
pathways that regulates progression of the cell cycle.35 Since TPP has shown to disturb 
mitochondrial functions, the hypothesis that TPP inhibits E2-induced cell viability and 
growth by altering the mitochondrial signaling pathways involved in the progression of the 
cell cycle is intriguingly applicable. 
Consistent with the above notion, TPP also inhibited E2-induced proliferation 
which was detected through BrdU incorporation into cellular DNA during cell proliferation 
in MCF-7 cells. In our model, cells were synchronized and held at the G1/S phase 
checkpoint by serum starvation and then transited toward the S phase by the addition of 
E2.30 Indeed, E2 has shown to significantly increase DNA synthesis which was mediated 
by mitochondrial ROS signaling.30 In this sense, TPP suppression of E2-induced DNA 
synthesis or S phase progression may relate, in part, to mitochondrial dynamics.  
There are few reports that have investigated the effect of estrogen on ΔΨm. A recent 
report suggested that low concentration of E2 (10 nM ≈ 2.7 ng/mL) could change the ΔΨm 
and increase the high ΔΨm percentage in human spermatozoa.36 Another report showed that 
E2 inhibits apoptotic proteins that mainly affect the ΔΨm during apoptosis and result in 
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supporting the ΔΨm.37 In contrast, Simpson et al. reported that high concentration of E2 (up 
to 100 μM ≈ 27 μg/mL) did not affect the ΔΨm of human neuroblastoma cells.38 However, 
since estrogen can increase the inner fluidity of the mitochondrial membrane, an increase 
in the ΔΨm results from the increased electron transfer rate.39 Also, our mitochondrial 
bioenergetics measurement data showed that E2 increased ΔΨm in MCF-7 cells (Figure 
3.4.4). Additionally, TPP, through its action at the ΔΨm, inhibited the E2-induced increase 
in ΔΨm. Therefore, the assumption that estrogen may have the ability to increase the 
mitochondrial membrane potential is very relevant and could be a key mechanism in the 
development of estrogen-dependent breast cancer. 
 ROS production in our estrogen-induced model was investigated, since it was 
suggested that the formation of ROS in mitochondria occurs at a high ΔΨm.40 Our data 
shows that the presence of TPP decreases the E2-induced ROS formation in MCF-7 cells. 
To confirm the source of ROS generated by our E2-induced model, we localized ROS 
using a mitochondrial ROS indicator. Our results showed that a significant proportion of 
E2-induced ROS is mitochondrial in origin and the presence of TPP decreases the E2-
induced mitochondrial superoxide, as a form of ROS, in MCF-7 cells. Several reports have 
suggested that E2 stimulates the formation of ROS in different cells, in-vitro. For instance, 
E2 has been shown to stimulate intracellular ROS production via mitochondrial signaling, 
which suggests a potential role of mitochondrial ROS as signal-transducing messengers in 
MCF-7 cells.22 Indeed, estrogen exposure has been shown to trigger ROS production, 
mainly mitochondrial ROS, involving the growth signaling of MCF-7 and vascular 
endothelial cells.10,30 In this regard, our results demonstrate that ROS formation is 
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consistent with ΔΨm measurements, and therefore suggest that estrogen modulation of ΔΨm 
may be involved, mechanistically, in the generation of ROS, or vice versa. 
Since DNA damage and repair are important factors in the development of human 
cancers,41 we investigated E2-induced DNA damage. It has been reported that E2 treatment 
induces DNA damage and increases γH2AX, an early marker of DNA double-strand 
breaks.32 Our data showed that E2 induces DNA damage and the co-treatment with TPP 
inhibits E2-induced DNA damage, and therefore suggest the E2-induced mitochondrial 
ROS as a possible mechanism in the DNA damage of estrogen-dependent breast cancer. 
In summary, our findings propose that TPP inhibition of E2-induced mitochondrial 
dynamics and metabolism hints for a possible mitochondrial function in cancer affected 
tissues. Further investigations are needed to clarify the exact mechanisms by which E2-
induced activities are inhibited by mitochondria-targeted cation. By providing a foundation 
for the utility of mitochondria-targeted lipophilic cations, such as TPP, this work opens the 
way for the rational design of mitochondria-targeted drugs directed against estrogen-
dependent breast tumors. 
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3.7 Supplementary Data 
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CHAPTER 4 
ANTITUMOR ACTIVITY OF EXTRACT AND MITOCHONDRIA-TARGETED 
BIOCONJUGATE OF ORIGANUM MAJORANA IN BREAST CANCER 
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4.1 Abstract 
Origanum majorana, commonly known as marjoram, is a perennial herb, which is widely 
used in the Middle East as a spice. It has been shown to possess extensive range of 
biological activity, including antioxidant, anti-inflammatory, and anti-tumor growth 
effects. Interestingly, the anticancer potential of O. majorana against breast cancer remains 
largely unexplored. The aim of this study was to evaluate the cytotoxic effects of O. 
majorana organic extract (OME) as well as a PEGylated bioconjugate of OME with 
triphenylphosphonium (P-OME-TPP) against human breast epithelial and cancer cell lines. 
Herein, the anticancer effect of O. majorana on three breast cell lines, MDA-MB231, 
MCF-7, and MCF-10A cells, was investigated. Triphenylphosphonium (TPP) cation was 
used to specifically deliver the bioconjugate to mitochondria. Determination of 
mitochondrial metabolic activity (cell viability) and cell density (cell growth) showed that 
OME blocked E2-induced cell viability and growth of breast cancer MCF-7 cells. Both 
OME and P-OME-TPP inhibited viability and growth of MDA-MB231 and MCF-7 cells, 
but no effect on normal breast epithelial MCF-10A cells was observed. Finally, the results 
also demonstrated that P-OME-TPP conjugate, compared to OME, was far more effective 
in exerting its cytotoxic effect through the inhibition of growth, and decrease in 
mitochondrial metabolic activity in both highly metastatic, triple negative MDA-MB-231 
and estrogen-dependent MCF-7 breast cancer cells. These findings offer a new perspective 
on the potential of O. majorana extract to be developed as a new therapy against breast 
tumors.  
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4.2 Introduction 
Breast cancer is the most common cancer in women and the second most common cancer 
among all cancers worldwide.1 These high rates are probably due to the interaction of 
multiple environmental and biological factors. These interactions make breast cancer a 
heterogeneous disease, which give rise to therapeutic challenges such as disease resistance 
and recurrence, and the requirement for immensely toxic therapy. Indeed, up to 50% of 
patients are treated with hormonal therapy and chemotherapy; and of them almost 35% are 
resistant to current therapy.2 Aggressive tumors are usually resistant to therapy; thus, 
treatments are not effective. The existing therapeutic agents used on aggressive tumors, 
such as chemotherapy, are extremely toxic.3 There is an urgent need to develop effective 
and less toxic therapy against aggressive breast cancer. To successfully produce a better 
treatment with increased efficacy and low toxicity, it is necessary to select therapies based 
on the clinical and molecular characteristics of the tumor, of which there are at least three 
significant subtypes, based on gene expression profiles.4 Estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) receptor 
status is very important in categorizing breast tumors to successfully predict outcome and 
help in controlling of the disease development.5  
Estrogens have a major role in breast tumor initiation and progression. 
Epidemiological and clinical evidences have associated the increased lifetime exposure to 
estrogens with high risk of developing breast cancer.6–8 Nevertheless, the mechanisms 
involved in estrogen-induced breast carcinogenesis are still unclear. Experimentally, 
estrogens are considered breast carcinogens, as a result of their ability to initiate and 
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promote the development of cancer.9–12 Precisely, ER-mediated signaling pathways are the 
most recognized pathways in estrogen carcinogenic mechanisms.13,14 As most of breast 
cancer hormonal therapies are designed for the ER-positive cancer, they are mainly limited 
to anti-estrogenic agents targeting ER.15 Selective estrogen receptor modulators (SERMs); 
such as Tamoxifen, and antiestrogens; such as ICI 182,780 (Fulvestrant) are commonly 
used in ER-positive tumor treatment.15 Even though SERMs might prevent the growth of 
cancer due to their actions at the ER, other contributing mechanisms cannot be excluded, 
since these compounds also inhibit metabolism and redox cycling of estrogen and act as 
free radical scavengers.16 Whereas, nearly 70% of newly diagnosed breast cancer patients 
have a positive expression of ER, approximately 50% of those patients develop resistance 
to most anti-estrogenic agents.17 In addition, breast cancer characterized by lack of ER, PR, 
and overexpression of HER2, often called triple-negative breast cancer (TNBC), is 
typically associated with poor prognosis due to aggressive tumor phenotypes and current 
lack of effective and specific therapies.18 The traditional chemotherapy drugs cause non-
specific toxicity, deteriorate the patient's quality of life, weaken the immune system, and 
result in off-target effects on normal tissues.19  
Mitochondria are important subcellular organelles that play a critical role in cellular 
metabolism, calcium homeostasis, redox signaling pathways, apoptosis and cell death.20 
Dysfunctional mitochondria are common among various diseases and specifically to cancer 
tumor cells, which is explained by the conversion of the source of metabolic energy from 
oxidative phosphorylation to active glycolysis and increased ROS formation.21 Although 
estrogen may be involved in breast carcinogenesis through increasing the mitochondrial-
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derived ROS, the precise mitochondrial mechanisms for estrogen-induced breast 
carcinogenesis are still unclear.22 For example, the most potent endogenous estrogen, 17-
β-estradiol (E2), was shown to promote DNA synthesis in breast cancer cells via 
mitochondrial oxidant signaling.22 Thus, mitochondrial targeting strategy has drawn 
attention, recently, as a cancer therapeutic strategy and several investigations in this area 
have been reported.23  
Accumulation of mitochondria-specific drugs is necessary in optimizing tumor-
targeted therapeutic agents. In this case, the triphenylphosphonium (TPP) cation have been 
used to deliver biologically active compound and molecules; such as antioxidants, to 
mitochondria, which indicates the inclusive utility of this approach for mitochondria 
targeting.24 TPP is a lipophilic cation that possess the property of being lipid-soluble, 
despite its total positive charge. This property allows TPP to cross the cell membrane 
phospholipid bilayers, as well as the mitochondrial membrane.25 The large membrane 
potential, approximately -180 mV, across the mitochondrial inner membrane is used to 
specifically deliver molecules to mitochondria. TPP conjugated to a therapeutic molecule 
will pass the cell membrane using the lipid-soluble property. The uptake into the cytoplasm 
across the plasma membrane is driven by the plasma membrane potential (-30 to -60 mV, 
internal).25 From the cytoplasm, the TPP conjugates are further accumulated into the 
mitochondria, which is driven by the mitochondrial membrane potential (ΔΨm). The 
accumulation of TPP conjugates in the cytoplasm and mitochondria is about 5-10 and 100-
500 fold, respectively, compared to the extracellular environment .25 
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An increasing number of studies have shown that phytochemicals are important 
with regards to their cancer chemopreventive properties and their ability to decrease tumor 
growth.26 Phytochemicals can regulate several pathways used by cancer cells in the 
processes of cell growth and proliferation, survival, angiogenesis, invasion, metastasis, and 
apoptosis.27 Origanum majorana, commonly known as marjoram, is worldwide perennial 
herb. It is utilized as a spice, flavoring agent, and has an ancient culinary and medicinal 
use.28 It has been used as a traditional medicine for various illnesses such as chest 
infections, cough, sore throat, rheumatism, cardiovascular diseases, abdominal pain, 
insomnia, anxiety disorder, as well as skin care.29,30 Several studies have reported that O. 
majorana is rich in phenolic compounds, which possess the capacity to scavenge free 
radicals and exhibit a strong antioxidant property.31 A few studies have reported the 
anticancer potential of O. majorana; however, it remains largely unexplored.32  
To specifically target the tumor with enhanced efficacy and reduced non-targeted 
toxicity, small molecule bioconjugation therapy usually used due to their unique physical 
and biological properties.33 Polyethylene glycol (PEG), is an amphiphilic polymer, 
provides electrostatic and steric stabilization, and a longer circulation half-life in vivo as 
well as functional-end groups for the attachment of targeting ligands.33 PEGylation of 
anticancer compounds is to protect the molecules from destruction by the 
reticuloendothelial system (RES) and, therefore, increase circulation time and drug 
accumulation in the tumors.34 In this study, O. majorana extract (OME) was used to 
synthesize mitochondria-targeted bioconjugate of O. majorana (P-OME-TPP) and its 
cytotoxicity in 17β-estradiol (E2) treated human breast epithelial and cancer cell lines was 
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evaluated. The antitumor property of OME and P-OME-TPP was measured using cell 
viability and cell growth assays.  
 
4.2 Materials and methods 
4.2.1 Chemicals and reagents.  
17β-Estradiol, (4-carboxybutyl) triphenylphosphonium (TPP) bromide, dimethylsulfoxide 
(DMSO), 3(4,5-dimethylthiazolyl-2)2,5-diphenyl tetrazolium bromide (MTT), 
sulforhodamine B (SRB), trichloroacetic acid (TCA), poly-(ethylene glycol)-4000 
[PEG4000; powder; MW 3500-4500], and block copolymer surfactant pluronic P123 were 
all purchased from Sigma-Aldrich (St. Louis, MO, USA). All tissue culture reagents were 
purchased from Invitrogen Corporation (Carlsbad, CA, USA), unless otherwise specified. 
4.2.2 Preparation of the O. majorana ethanolic extract (OME).  
O. marjorana was obtained from a herbal store located in the Madinah region of Saudi 
Arabia. The extract was prepared as described by Dhaheri et al.32 Briefly, 5.0 g of the dried 
leaves were ground to a powder using a porcelain pestle and mortar. The powder was 
suspended in 100 mL of 70% (v/v) absolute ethanol and the mixture kept in the dark for 72 
h at 4 °C without stirring. Using a sintered glass funnel, the mixture was filtered and the 
filtrate then evaporated to dryness using a rotary evaporator at RT. The resulting green 
powder residue was kept under vacuum for 3 h and its mass then recorded. 
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4.2.3 Synthesis of P-OME-TPP bioconjugate.  
The bioconjugate was synthesized according to Bhattacharya et al. with minor 
modification.35 Briefly, 120 mg of dry OME was added in 20 mL of ethanol. Next, 20 mg 
of surfactant (P123) was added to the mixture and stirred briefly. Then, 20 mg of TPP was 
added to the mixture and stirred for 15 min. PEG was prepared by homogenizing 10 g of 
PEG4000 in 50 mL of deionized water, using ice-bath sonication for 20-30 min. When the 
PEG was completely dissolved, the OME-TPP mixture was drop-wise mixed with PEG 
under sonicating condition. When the addition was completed, the mixture was kept under 
sonicating condition for another 30 min, which was followed by an overnight stirring at 
RT. Next day, the organic solvent (ethanol) present in suspension was evaporated by a 
rotary evaporator and a solution of P-OME-TPP conjugate was obtained. 
4.2.4 Characterization of P-OME-TPP bioconjugate by UV/Vis Spectrophotometry. 
PEG, TPP, P123, OME, and P-OME-TPP bioconjugate were characterized by measuring 
the absorbance by UV/Vis Spectrophotometer at range of 200-450 nm. 
4.2.5 Cell culture.  
The estrogen-dependent breast cancer (MCF-7), metastatic breast cancer (MDA-MB231), 
and normal epithelial breast (MCF-10A) cells were routinely cultured in phenol red 
DMEM-F12 media (1:1) supplemented with 5% (v/v) fetal bovine serum (FBS), 100 
IU/mL penicillin, and 100 µg/mL streptomycin (complete media) at 37 °C in a 5% CO2 
humidified incubator. For experimental purposes, culture media were changed to starvation 
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media (serum free media + antibiotics) and allowed to incubate for 48 h prior to 
commencement of all experiments, unless otherwise indicated. 
4.2.6 Cell viability.  
MTT was used to determine cell viability according to the manufacturer's protocol.36 In 
brief, MCF7, MCF-10A, and MDA-MB231 cells were seeded in three separate 96-well 
plates (approx. 7500 cells/well) overnight in complete media and serum starved for 48 h 
prior to treatment with OME, P-OME-TPP, and OME with E2 for 24 h or 48 h. Then, 20 
µL of (5 mg/mL) MTT was added to each well. After incubation for 3.5 h at 37 °C, the 
media was carefully removed and 100 µL of MTT solvent (100% DMSO) was added to 
each well. The plates were then covered with aluminium foil and agitated on shaker for 15 
min. Absorbance was recorded at 590 nm (reference λ at 620 nm) on a Tecan Genios 
microplate reader. 
4.2.7 Cell growth.  
SRB was used to determine cell growth as described by Skehan et al.37 Briefly, cells were 
seeded in three separate 96-well plates (approx. 7500 cells/well) for 24 h in complete media 
and serum starved for 48 h prior to adding the various cell treatments for 24 h or 48 h. The 
cells were then fixed with 50% TCA solution, layered on top of the existing medium, and 
chilled to 4 °C. After 1 h of incubation at 4 °C, the plates were rinsed four times with 
distilled water. Then 100 µL of 0.4% (w/v) SRB was added to cover the bottom of the well 
and allowed to stain for 20 min. Unbound dye was removed by four washes with 1% acetic 
acid, and protein-bound dye was extracted with 10 mM unbuffered Tris base [tris 
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(hydroxymethyl) aminomethane]. Absorbance was determined at 590 nm (reference λ at 
620 nm) on a Tecan Genios microplate reader. 
4.2.8 Statistical Analysis.  
Statistical analyses was performed using GraphPad Prism, version 6 (GraphPad, CA, 
USA). The data was evaluated using one-way ANOVA and Tukey's multiple comparisons 
tests to compare the values between groups. The level of statistical significance was set at 
P <0.05. 
 
4.3 Results  
OME inhibits E2-induced cellular viability of estrogen-dependent breast cancer cells.  
The time- and dose-dependent effect of E2 (100 pg/mL and 100 ng/mL) and co-treatment 
of OME with E2 (300 µg/mL) on the viability of MCF-7, MDA-MB231, and MCF-10A 
cells in serum-free conditions for 24 h and 48 h was tested. As shown in Figure 4.3.1, a 
significant time- and dose-dependent increase in cell viability was observed for both E2 
100 pg/mL (p <0.0001) and E2 100 ng/mL (p <0.0001) for MCF-7 cells for both periods 
24 h and 48 h (Figure 4.3.1A). This increase was not observed for MDA-MB231 (Figure 
4.3.1B) nor MCF-10A (Figure 4.3.1C) cells. This confirms the estrogen-dependency of 
MCF-7 cells viability. Interestingly, the OME treatment had a significant time and dose-
dependent decrease in E2-induced cell viability of MCF-7. The cell viability of E2 (100 
pg/mL and 100 ng/mL) treatments were significantly inhibited by co-treatment with OME 
(p <0.0001). The serum-free conditions used in these experiments were optimal for  
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Figure 4.3.1 OME inhibited E2-induced MCF-7 cell viability, determined by MTT assay. Cell 
viability for (A) MCF-7; (B) MDA-MB231; (C) MCF-10A. Cells were cultured for 24 h in 
complete media then serum starved for 48 h prior to treatment with E2, OME, or E2 co-treatment 
with OME for 24 h and 48 h. Results are expressed as the mean ± S.E.M. of three independent 
experiments with control (ethanol) set as 100% cell viability. * (p <0.05), **(p <0.01), and ****(p 
<0.0001) treatments are significantly different from control or corresponding E2 concentrations.  
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observing E2-induced effect on breast cancer cells, since serum deprivation synchronizes 
cells in the G0/G1 phase of the cell cycle.38 
OME inhibits E2-induced cell growth of estrogen-dependent breast cancer cells.  
To confirm the inhibition of MCF-7 cell viability by co-treatment of OME with E2, SRB 
assay was used to determine the cell growth for the three cell lines. A significant time- and 
dose-dependent increase in cell growth was noticed for both E2 concentrations (p <0.0001) 
on MCF-7 cell (Figure 4.3.2A). However, this was not noticed for MDA-MB231 (Figure 
4.3.2B) nor MCF-10A (Figure 4.3.2C) cells. Intriguingly, OME had a significant time- and 
dose-dependent inhibition in E2-induced cell growth of MCF-7 cells. The cell growth of 
E2 (100 pg/mL and 100 ng/mL) treatments were significantly inhibited by co-treatment 
with OME (p <0.0001). These results demonstrated and confirmed that OME inhibits E2-
induced cell viability and growth of MCF-7 cells. 
Confirmation of conjugation of P-OME-TPP bioconjugate by UV/Vis 
Spectrophotometry. 
The presence of the OME in PEG conjugate was evaluated by UV-Visible spectroscopy. 
The UV-Visible spectra of all conjugate components including poly-(ethylene glycol) 
(PEG4000), triphenylphosphonium (TPP), surfactant (P123), O. majorana extract (OME), 
and bioconjugate of O. majorana (P-OME-TPP) are showed in Figure 4.3.3. The PEG4000 
showed no absorbance peak (Figure 4.3.3A), whereas TPP showed absorbance peak at 202 
nm (Figure 4.3.3B), P123 at 204 nm (Figure 4.3.3C), OME at 208 nm, 287 nm, and 328 
nm (Figure 4.3.3D), and P-OME-TPP at 225 nm, 268 nm, 275 nm and 329 nm (Figure  
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Figure 4.3.2 OME inhibited E2-induced MCF-7 cell growth, determined by SRB assay. Cell 
growth for (A) MCF-7; (B) MDA-MB231; (C) MCF-10A. Cells were cultured for 24 h in complete 
media then serum starved for 48 h prior to treatment with E2, OME, or E2 co-treatment with OME 
for 24 h and 48 h. Results are expressed as the mean ± S.E.M. of three independent experiments 
with control (ethanol) set as 100% cell growth. ***(p <0.001) and ****(p <0.0001) treatments are 
significantly different from control or corresponding E2 concentrations.  
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Figure 4.3.3 Analysis of P-OME-TPP bioconjugate components determined via UV/Vis 
Spectrophotometry. PEG, TPP, P123, OME, and P-OME-TPP were characterized by measuring 
the absorbance by UV/Vis Spectrophotometer at range of 200-450 nm. The absorbance peaks of 
all P-OME-TPP components were compared with P-OME-TPP peaks to identify new emerging 
peaks as a sign successful conjugation.  
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4.3.3E). The new absorbance peaks showed at 225 nm, 268 nm, 275 nm and 329 nm for P-
OME-TPP indicated the presence of TPP, P123, and OME within the PEGylated 
bioconjugate, thereby confirming the proper preparation of the bioconjugate of O. 
majorana (P-OME-TPP). 
OME and P-OME-TPP treatment inhibit the cellular viability of estrogen-dependent 
breast cancer (MCF-7) and metastatic breast cancer (MDA-MB231) cells. 
Initially, the dose- and time-dependent effect OME and P-OME-TPP on the viability of 
MCF-7, MDA-MB231, and MCF-10A cells in serum-free conditions was tested. As shown 
in Figure 4.3.4, both MCF-7 and MDA-MB231 treated with OME had a significant time- 
and dose-dependent decrease in their viability. However, MCF-10A treated with OME did 
not influence cell viability. MCF-7 cell viability was significantly inhibited by OME 
concentrations of 300 µg/mL (p <0.001), 450 µg/mL and 600 µg/mL (p <0.0001) for the 
24 h period. Also, it was significantly inhibited by OME concentrations of 100 µg/mL, 300 
µg/mL, 450 µg/mL and 600 µg/mL (p <0.0001) for the 48 h period (Figure 4.3.4A). MDA-
MB231 cell viability was also significantly inhibited by OME concentrations of 450 µg/mL 
and 600 µg/mL (p <0.0001) for the 24 h period. It was also significantly inhibited by OME 
concentrations of 100 µg/mL (p <0.01), 300 µg/mL, 450 µg/mL and 600 µg/mL (p 
<0.0001) for the 48 h period (Figure 4.3.4B). MCF-10A did not show significant decrease 
in viability by OME concentrations for both 24 h and 48 h periods (Figure 4.3.4C).  
Furthermore, both MCF-7 and MDA-MB231 cells treated with P-OME-TPP had a 
significant time- and dose-dependent decline in their viability (Figure 4.3.4A and B). 
However, this decrease was not observed for MCF-10A cells. MCF-7 cell viability was  
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Figure 4.3.4 OME and P-OME-TPP bio-conjugate decreased MDA-MB231 and MCF-7 cell 
viability, determined by MTT assay. Cell viability for (A) MCF-7; (B) MDA-MB231; (C) MCF-
10A. Cells were cultured for 24 h in complete media then serum starved for 48 h prior to treatment 
with OME or P-OME-TPP for 24 h and 48 h. Results are expressed as the mean ± S.E.M. of three 
independent experiments with control (ethanol) set as 100% cell viability.  
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significantly inhibited by P-OME-TPP concentrations of 100 µg/mL (p <0.01), 300 µg/mL 
(p <0.001), 450 µg/mL and 600 µg/mL (p <0.0001) for the 24 h period. Also, it was 
significantly inhibited by all P-OME-TPP concentrations (p <0.0001) for the 48 h period 
(Figure 4.3.4A). For MDA-MB231, P-OME-TPP significantly inhibited cell viability of 
MDA-MB213 at 100 µg/mL (p <0.05), 300 µg/mL (p <0.001), 450 µg/mL and 600 µg/mL 
(p <0.0001) for the 24 h period. Also, MDA-MB231 cell viability was significantly 
inhibited by all P-OME-TPP concentrations (p <0.0001) for the 48 h period (Figure 
4.3.4B). MCF-10A did not display any significant inhibition in viability by P-OME-TPP 
concentrations for both 24 h and 48 h periods (Figure 4.3.4C). Also, P-OME-TPP conjugate 
individual components, consisted of PEG, P123, and TPP, did not show any significant 
effect on all treated cell lines (Figure 4.3.1S).   
Compared to OME treatment, P-OME-TPP significantly inhibited the viability of 
MCF-7 with a concentration as low as 100 µg/mL (p <0.01), whereas OME did not affect 
the viability at the same concentration for the 24 h period. Also, the half maximal inhibitory 
concentration (IC50) of cell viability was lower for P-OME-TPP (276.6 µg/mL for 24 h and 
123.8 µg/mL for 48 h) compared to OME (400 µg/mL for 24 h and 205.8 µg/mL for 48 h) 
(Table 4.3.1). Moreover, P-OME-TPP significantly inhibited the viability of MDA-MB231 
with concentrations as low as 100 µg/mL (p <0.05) and 300 µg/mL (p <0.001), whereas 
OME did not show a significant effect on the viability at the same concentration for the 24 
h period. Also, the IC50 of cell viability was lower for P-OME-TPP (337.5 µg/mL for 24 h 
and 158.6 µg/mL for 48 h) compared to OME (481 µg/mL for 24 h and 289.6 µg/mL for 
48 h) (Table 4.3.1).  
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Table 4.3.1 OME and P-OME-TPP assessment of IC50 for MCF-7 and MDA-MB231 cells 
viability.  
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OME and P-OME-TPP inhibited cell growth of MCF-7 and MDA-MB231 cells.  
To confirm the inhibition of MCF-7 and MDA-MB231 cell viability by OME and P-OME-
TPP, SRB assay, which detects cellular protein, was used to determine the cell growth for 
the three cell lines. The dose- and time-dependent effect of OME and P-OME-TPP on the 
growth of MCF-7, MDA-MB231, and MCF-10A cells in serum-free conditions was tested. 
As shown in Figure 4.3.5, both MCF-7 and MDA-MB231 treated with OME had a 
significant time- and dose-dependent decrease in their growth. However, this decrease was 
not observed for MCF-10A cells. MCF-7 cell growth was significantly inhibited by OME 
concentrations of 100 µg/mL (p <0.05), 300 µg/mL (p <0.001), 450 µg/mL and 600 µg/mL 
(p <0.0001) for the 24 h period. Also, it was significantly inhibited by all OME 
concentrations (p <0.0001) for the 48 h period (Figure 4.3.5A). MDA-MB231 cell growth 
was also significantly inhibited by OME concentrations of 300 µg/mL (p <0.001), 450 
µg/mL and 600 µg/mL (p <0.0001) for the 24 h period. It was also significantly inhibited 
by all OME concentrations (p <0.0001) for the 48 h period (Figure 4.3.5B). MCF-10A did 
not show a significant decrease in growth by OME concentrations for both 24 h and 48 h 
periods (Figure 4.3.5C).  
Moreover, both MCF-7 and MDA-MB231 treated with P-OME-TPP had a 
significant time- and dose-dependent decrease in their growth (Figure 4.3.5A & B). 
However, this was not noticed in MCF-10A treated with P-OME-TPP. MCF-7 cell growth 
was significantly inhibited by P-OME-TPP concentrations of 100 µg/mL (p <0.001), 300 
µg/mL (p <0.001), 450 µg/mL and 600 µg/mL (p <0.0001) for the 24 h period. Also, it was 
significantly inhibited by all OME concentrations (p <0.0001) for the 48 h period (Figure  
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Figure 4.3.5 OME and P-OME-TPP decreased MDA-MB231 and MCF-7 cell growth, 
determined by SRB assay. Cell growth for (A) MCF-7; (B) MDA-MB231; (C) MCF-10A. Cells 
were cultured for 24 h in complete media then serum starved for 48 h prior to treatment with OME 
or P-OME-TPP for 24 h and 48 h. Results are expressed as the mean ± S.E.M. of three independent 
experiments with control (ethanol) set as 100% cell growth.  
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4.3.5A). For MDA-MB231, P-OME-TPP significantly inhibited cell growth at 100 µg/mL 
(p <0.01), 300 µg/mL, 450 µg/mL and 600 µg/mL (p <0.0001) for the 24 h period. Also, 
MDA-MB231 cell growth was significantly inhibited by all P-OME-TPP concentrations 
(p <0.0001) for the 48 h period (Figure 4.3.5B). MCF-10A had no significant inhibition in 
viability by OME concentrations for both 24 h and 48 h periods (Figure 4.3.5C). Moreover, 
P-OME-TPP conjugate individual constituents, contained PEG, P123, and TPP, did not 
show any substantial effect on all treated cell lines (Figure 4.3.2S). 
Additionally, the IC50 of MCF-7 cell growth was lower for P-OME-TPP (251.7 
µg/mL for 24 h and 131.2 µg/mL for 48 h) compared to OME (387.9 µg/mL for 24 h and 
192.7 µg/mL for 48 h) (Table 4.3.2). Furthermore, P-OME-TPP significantly inhibited the 
growth of MDA-MB231 with a concentration as low as 100 µg/mL (p <0.01), whereas 
OME did not affect the growth at the same concentration for the 24 h period. The IC50 of 
cell growth was also lower for P-OME-TPP (271.9 µg/mL for 24 h and 122.1 µg/mL for 
48 h) compared to OME (389.7 µg/mL for 24 h and 212.9 µg/mL for 48 h) (Table 4.3.2). 
Altogether, these results confirmed the cytotoxic effect of OME and P-OME-TPP on MCF-
7 and MDA-MB231 cells. 
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Table 4.3.2 OME and P-OME-TPP assessment of IC50 for MCF-7 and MDA-MB231 cells 
growth.  
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4.4 Discussion 
In the present study, we have shown for the first time that the O. majorana ethanolic extract 
was able to inhibit estrogen-induced viability and growth of MCF-7 cells in a time- and 
concentration-dependent manner. We have also demonstrated that the P-OME-TPP 
bioconjugate compared to OME was far more effective in exerting its cytotoxic effect 
through the induction of growth arrest and inhibition of mitochondrial metabolic activity 
which resulted in cell death of MCF-7 and the highly metastatic triple negative MDA-MB-
231 cells, in a time- and concentration-dependent manner. 
In fact, estrogens are considered risk factors for breast cancer development and 
progression for estrogen-dependent cell, such as MCF-7, compared to estrogen 
independent breast cancer cells, such as MDA-MB231, through the induction of cell 
proliferation and differentiation.39 Indeed, estrogen-induced growth, DNA synthesis, 
proliferation, and ROS production have been reported for several estrogen-dependent 
cells.38,40–44 Noteworthy, mitochondrial signaling pathways involved in the progression of 
cell cycle has been reported to regulate estrogen-induced cell growth.45 Our results 
corroborate previous studies that demonstrated positive relationships between E2 and cell 
viability and growth in MCF-7 cells. On the contrary, MDA-MB231 and MCF-10A show 
no correlation with these E2 induced endpoints.22,38,40,45 
Inhibition of cell cycle progress and induction of apoptosis and cell death are 
essential mechanisms of the traditional anti-cancer treatments. Several natural compounds 
have been reported to possess chemopreventive properties via these two mechanisms.46–49 
For example, O. majorana is reported to exhibit cytotoxic, membrane and DNA damaging 
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effects on human lung cancer cells.50 Moreover, Abdel-Massih et al. reported that O. 
majorana extracts exhibit anti-proliferative effects and high antioxidant activity on human 
lymphoblastic leukemia cells.51 Our results showed profound findings when E2-induced 
cellular activities are co-treated with OME. E2 co-treated with OME, time- and 
concentration-responsively, inhibits cellular activities in MCF-7 cells. E2-induced viability 
and growth are remarkably decreased when co-treated with OME. This suggests that the 
anti-proliferative effect of OME, by induction of apoptosis,51 could inhibit E2-induced 
viability and growth. 
There is a growing interest in targeted therapy using multiple bioactive and delivery 
molecules affecting several targets and/or pathways with enhanced efficacy and reduced 
non-targeted toxicity.33 One of these approaches is the small molecule bioconjugation 
which could be achieved by PEGylation of anticancer compounds and delivery molecules 
to protect the molecules from destruction and increased circulation time and bioconjugate 
accumulation in the tumors.34 Thus, we have successfully PEGylated OME with TPP, to 
specifically deliver the bioconjugate to mitochondria,24 and tested it on MFC-7, MDA-
MB231, and MCF-10A cells. Our results showed interesting findings when cells are treated 
with OME and P-OME-TPP. First, we demonstrated for the first time that O. majorana 
possesses potent anti-proliferative effects against the estrogen-dependent breast cancer cell 
line, MCF-7. In fact, O. majorana extract, time- and concentration-responsively, inhibits 
the viability and growth of MCF-7 cells. Indeed, Al Dhaheri et al. reported that O. 
majorana extract shows anticancer activity through inducing cell cycle arrest and apoptosis 
of the highly proliferative and invasive MDA-MB231 breast cancer cell line.32 They also 
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reported that O. majorana exhibits anti-metastatic and anti-tumor growth activities by 
inhibiting NFκB signaling and nitric oxide production of MDA-MB231 cells.52 Similarly, 
we showed that OME, time- and concentration-dependently, inhibits the viability and 
growth of MDA-MB231 cells. In contrast, MCF-10A cells treated with OME show no 
significant change regarding their viability and growth. 
Mitochondria play a major role in apoptosis and cell death as well as regulating cell 
growth and proliferation, which make them a potential target in cancer therapy.20 Herein, 
we demonstrate that the bioconjugate of O. majorana has potent cytotoxic effects against 
MCF-7 and MDA-MB231 cells. Indeed, our results showed that P-OME-TPP was much 
more effective regarding its cytotoxicity compared to OME in both MCF-7 and MDA-
MB231, according to the calculated IC50. This suggests that the inhibitory mechanism of 
P-OME-TPP could be associated with mitochondria by altering the mitochondrial signaling 
pathways involved in cell growth and proliferation. 
In summary, this study clearly demonstrated, for the first time, that O. majorana 
extract was able to inhibit estrogen-induced viability and growth of MCF-7 cells. In 
addition, OME possesses cytotoxic effects against MCF-7 and MDA-MB-231 cells 
through the inhibition of cell viability and growth. Our results also demonstrated that P-
OME-TPP conjugate, compared to OME, was far more effective in exerting its cytotoxic 
effect through the inhibition of cell growth and viability in both highly metastatic, triple 
negative MDA-MB231 and estrogen-dependent MCF-7 breast cancer cells. Thus, our 
findings offer a new perspective on the potential of O. majorana extract to be developed 
as a promising chemopreventive and new therapy against breast tumors.  
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4.6 Supplementary Data 
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Figure 4.3.2S 
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CHAPTER 5 
CONCLUSION 
The purpose of this dissertation was to investigate the mitotoxic and cytotoxic effects of 
triphenylphosphonium cation (TPP) and Origanum majorana extract (OME) as well as 
PEGylated bioconjugate of OME with TPP (P-OME-TPP) against normal human breast 
epithelial and cancer cell lines. The novel concept of this dissertation was to use a 
bioconjugation approach that involves PEGylation of natural anti-tumor compounds and 
specific mitochondria targeting molecules for specifically preventing growth of breast 
cancer and possibly other types of cancers. Thus, its hypothesized that novel biodegradable 
and mitochondria-targeted bioconjugate of OME with PEG and TPP inhibits the growth of 
breast cancer cells. 
 Initially, the effect of estrogen (E2), TPP, and co-treatment of E2 with TPP in 
estrogen-dependent breast cancer (MCF-7), metastatic breast cancer (MDA-MB231), and 
normal epithelial breast (MCF-10A) cells was tested to determine possible mechanisms by 
which mitochondria contribute to the growth of breast cancer. Our findings revealed that 
E2-induced metabolic activity, proliferation, DNA damage, and ROS production were 
inhibited by TPP in MCF-7 cells. Since TPP is a mitochondria-targeted lipophilic cation 
and is shown to imbalance mitochondrial function, this inhibitory mechanism proposes for 
a potential contribution of mitochondria in estrogen-induced carcinogenesis. Overall, these 
findings offer a new perspective on the utility of mitochondria-targeted lipophilic cation 
TPP as a promising new class of targeted-drugs for the treatment of estrogen-dependent 
breast tumors. 
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 Then, the potential cytotoxic effects of OME and P-OME-TPP in MCF-7, MDA-
MB213, and MCF-10A cells were tested to determine the possible antitumor properties of 
OME and P-OME-TPP as a potential breast cancer therapy. Our findings demonstrated that 
300 µg/mL of OME was able to significantly inhibit E2-induced metabolic activity and 
growth of MCF-7 cells. Furthermore, OME and P-OME-TPP were able induce cytotoxic 
effects in MCF-7 and MDA-MB231 cells, in time- and dose-dependent manner. Indeed, 
our findings revealed that synthesized P-OME-TPP was far more effective in exerting 
cytotoxic effects compared to OME in both MCF-7 and MDA-MB231 cells. Contrastingly, 
normal epithelial breast MCF-10A cells treated with OME and P-OME-TPP exhibited no 
change in regard to their viability and growth. Altogether, our findings offer a new 
perspective on the potential of O. majorana plant extract to be developed as a promising 
chemopreventive and new therapy against breast tumors.  
5.1 Directions for future research 
By providing a foundation for the utility of mitochondria-targeted cations, such as TPP, 
and natural antitumor compounds, such as OME, the results of this dissertation are intended 
to open the way for the rational design of mitochondria-targeted drugs that involve natural 
antitumor compounds directed against breast tumors and potentially many other tumor 
types.  
Indeed, further investigations are needed to clarify the exact mechanisms by which 
E2-induced activities are inhibited by mitochondria-targeted cation. Since our results 
indicate that mitochondrial function involved in estrogen induced effects, further research 
regarding mitochondrial growth signaling and biogenesis are greatly needed. For instance, 
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investigation of mitochondrial signaling pathways that regulates progression of the cell 
cycle, which are involved in cell growth and proliferation, will clarify the E2-induced 
mechanisms that inhibited by mitochondria-targeted molecule. 
Furthermore, investigating the exact mechanisms by which OME and P-OME-TPP 
are exhibiting cytotoxic effects are needed. First, chemical composition of O. majorana 
bioactive extract could be identified to characterize its active phenolic compounds. Also, 
several mechanisms, by which OME and P-OME-TPP is inducing its effects, could be 
investigated. For instance, the effects of OME and P-OME-TPP on cell cycle and apoptosis 
could be examined by measuring the levels of several cell cycle and apoptosis control 
proteins; such as cyclin-dependent kinase, survivin, tumor necrosis factor-α, caspase 8, 
caspase 3, PARP, and p21. Moreover, testing our hypothesis in vivo would be another area 
for future research. Xenografted tumors in chick embryos could be used to investigate 
OME and P-OME-TPP effect on tumor growth in vivo. Toxicity could be evaluated by 
comparing the number of deceased embryos in OME- P-OME-TPP-treated and control 
embryos. Finally, OME and P-OME-TPP ability to inhibit metastasis could be assessed by 
comparing the number of nodules in OME and P-OME-TPP treated tumors. This is a new 
direction of research that may provide the foundation for clinical research studies of 
mitochondria targeted and natural antitumor molecule-based therapy for the prevention and 
treatment of breast cancer.  
118 
 
VITA 
 
MOHANNAD MRWAN GAROUB 
 
 
2006-2009    B.A., Biology 
Purdue University 
Indianapolis, Indiana 
 
2008-2010    Research Specialist 
Department of Hematology/Oncology 
Indiana University Hospital 
Indianapolis, Indiana 
 
2008-2009    President 
Saudi Students Club-Indiana University Purdue University 
Indianapolis, Indiana 
 
2011-2013    M.P.H., Environmental and Occupational Health 
Florida International University 
Miami, Florida 
 
2014 -present    Lecturer 
College of Public Health and Health Informatics 
Umm Al-Qura University 
Makkah, Saudi Arabia 
 
2015 -2017    Ph.D. Candidate, Public Health 
Department of Environmental and Occupational Health 
Florida International University 
Miami, Florida 
 
 
 
PUBLICATIONS AND PRESENTATIONS 
 
Garoub, M., Karbaschi, M., Roy, D., and Cooke, M. (2017). Influence of estrogen on 
mitochondria in estrogen-dependent breast cancer. (Prepared for submission). 
 
Garoub, M., Karbaschi, M., Wnuk, S., and Cooke, M. (2017). Antitumor activity of 
extract and mitochondria-targeted bioconjugate of origanum majorana in breast 
cancer. (Prepared for submission). 
 
119 
 
Garoub, M. (2017). Current status of targeting breast cancer stem cells using small 
molecule-based therapy for triple negative aggressive breast cancer. (Prepared for 
submission). 
 
Garoub, M., Das, J., Wnuk, S., and Roy, D. (2016). Origanum majorana organic extract 
induces senescence and autophagic cell death in breast cancer cells through 
influencing mitochondrial metabolism. Poster presentation, AACR Annual 
Meeting, New Orleans, LA. 
 
Roy, D., Morgan, M., Yoo, C., Deoraj, A., Roy, S., Yadav, V., Garoub, M., Assaggaf, H., 
and Doke, M. (2015). Integrated bioinformatics, environmental epidemiologic and 
genomic approaches to identify environmental and molecular links between 
endometriosis and breast cancer. Int. J. Mol. Sci. 16(10), 25285-25322. 
 
Garoub, M., Roy, D., Das, J., and Wnuk, S. (2015). Influence of mitochondrial 
bioenergetics on the development of estrogen-dependent breast cancer. Poster 
presentation, AACR Annual Meeting, Philadelphia, PA. 
 
